id	sid	tid	token	lemma	pos
ijpds-3575	1	1	singh	singh	PROPN
ijpds-3575	1	2	et	et	PROPN
ijpds-3575	1	3	al	al	PROPN
ijpds-3575	1	4	.	.	PROPN
ijpds-3575	1	5	molnupiravir	molnupiravir	PROPN
ijpds-3575	1	6	and	and	CCONJ
ijpds-3575	1	7	favipiravir	favipiravir	PROPN
ijpds-3575	1	8	in	in	ADP
ijpds-3575	1	9	sars	sars	PROPN
ijpds-3575	1	10	-	-	PUNCT
ijpds-3575	1	11	cov-2	cov-2	PART
ijpds-3575	1	12	vol	vol	NOUN
ijpds-3575	1	13	1	1	NUM
ijpds-3575	1	14	|	|	ADV
ijpds-3575	1	15	issue	issue	VERB
ijpds-3575	1	16	3	3	NUM
ijpds-3575	1	17	|	|	ADV
ijpds-3575	1	18	oct	oct	PROPN
ijpds-3575	1	19	dec	dec	PROPN
ijpds-3575	1	20	2022	2022	NUM
ijpds-3575	1	21	indian	indian	PROPN
ijpds-3575	1	22	j	j	PROPN
ijpds-3575	1	23	pharm	pharm	PROPN
ijpds-3575	1	24	drug	drug	PROPN
ijpds-3575	1	25	studies	study	NOUN
ijpds-3575	1	26	|	|	ADV
ijpds-3575	1	27	73	73	NUM
ijpds-3575	1	28	review	review	NOUN
ijpds-3575	1	29	article	article	NOUN
ijpds-3575	1	30	molnupiravir	molnupiravir	PROPN
ijpds-3575	1	31	and	and	CCONJ
ijpds-3575	1	32	favipiravir	favipiravir	NOUN
ijpds-3575	1	33	in	in	ADP
ijpds-3575	1	34	the	the	DET
ijpds-3575	1	35	therapeutics	therapeutic	NOUN
ijpds-3575	1	36	of	of	ADP
ijpds-3575	1	37	sars	sar	NOUN
ijpds-3575	1	38	-	-	PUNCT
ijpds-3575	1	39	cov-2	cov-2	PART
ijpds-3575	1	40	a	a	DET
ijpds-3575	1	41	review	review	NOUN
ijpds-3575	1	42	ayush	ayush	ADJ
ijpds-3575	1	43	singh1	singh1	PROPN
ijpds-3575	1	44	,	,	PUNCT
ijpds-3575	1	45	2	2	NUM
ijpds-3575	1	46	,	,	PUNCT
ijpds-3575	1	47	riya	riya	PROPN
ijpds-3575	1	48	sehgal1	sehgal1	PROPN
ijpds-3575	1	49	,	,	PUNCT
ijpds-3575	1	50	karamjit	karamjit	ADJ
ijpds-3575	1	51	kaur1	kaur1	PROPN
ijpds-3575	1	52	,	,	PUNCT
ijpds-3575	1	53	manju1	manju1	PROPN
ijpds-3575	1	54	,	,	PUNCT
ijpds-3575	1	55	jatin	jatin	PROPN
ijpds-3575	1	56	isher1	isher1	PROPN
ijpds-3575	1	57	,	,	PUNCT
ijpds-3575	1	58	3	3	NUM
ijpds-3575	1	59	,	,	PUNCT
ijpds-3575	1	60	neeru	neeru	ADJ
ijpds-3575	1	61	kumari1	kumari1	NOUN
ijpds-3575	1	62	,	,	PUNCT
ijpds-3575	1	63	4	4	NUM
ijpds-3575	1	64	from	from	ADP
ijpds-3575	1	65	,	,	PUNCT
ijpds-3575	1	66	1department	1department	NUM
ijpds-3575	1	67	of	of	ADP
ijpds-3575	1	68	pharmacy	pharmacy	NOUN
ijpds-3575	1	69	,	,	PUNCT
ijpds-3575	1	70	global	global	ADJ
ijpds-3575	1	71	group	group	NOUN
ijpds-3575	1	72	of	of	ADP
ijpds-3575	1	73	institutes	institutes	PROPN
ijpds-3575	1	74	,	,	PUNCT
ijpds-3575	1	75	2department	2department	NUM
ijpds-3575	1	76	of	of	ADP
ijpds-3575	1	77	production	production	NOUN
ijpds-3575	1	78	,	,	PUNCT
ijpds-3575	1	79	alkem	alkem	PROPN
ijpds-3575	1	80	laboratories	laboratory	NOUN
ijpds-3575	1	81	limited	limit	VERB
ijpds-3575	1	82	,	,	PUNCT
ijpds-3575	1	83	baddi	baddi	PROPN
ijpds-3575	1	84	,	,	PUNCT
ijpds-3575	1	85	solan	solan	PROPN
ijpds-3575	1	86	,	,	PUNCT
ijpds-3575	1	87	himachal	himachal	PROPN
ijpds-3575	1	88	pradesh	pradesh	PROPN
ijpds-3575	1	89	,	,	PUNCT
ijpds-3575	1	90	3department	3department	NUM
ijpds-3575	1	91	of	of	ADP
ijpds-3575	1	92	quality	quality	NOUN
ijpds-3575	1	93	assurance	assurance	NOUN
ijpds-3575	1	94	,	,	PUNCT
ijpds-3575	1	95	kwality	kwality	PROPN
ijpds-3575	1	96	pharmaceuticals	pharmaceuticals	PROPN
ijpds-3575	1	97	ltd	ltd	PROPN
ijpds-3575	1	98	.	.	PROPN
ijpds-3575	1	99	,	,	PUNCT
ijpds-3575	1	100	4department	4department	NUM
ijpds-3575	1	101	of	of	ADP
ijpds-3575	1	102	quality	quality	NOUN
ijpds-3575	1	103	control	control	NOUN
ijpds-3575	1	104	,	,	PUNCT
ijpds-3575	1	105	kwality	kwality	PROPN
ijpds-3575	1	106	pharmaceuticals	pharmaceuticals	PROPN
ijpds-3575	1	107	ltd	ltd	PROPN
ijpds-3575	1	108	.	.	PROPN
ijpds-3575	1	109	,	,	PUNCT
ijpds-3575	1	110	amritsar	amritsar	PROPN
ijpds-3575	1	111	,	,	PUNCT
ijpds-3575	1	112	punjab	punjab	PROPN
ijpds-3575	1	113	,	,	PUNCT
ijpds-3575	1	114	india	india	PROPN
ijpds-3575	1	115	correspondence	correspondence	NOUN
ijpds-3575	1	116	to	to	PART
ijpds-3575	1	117	:	:	PUNCT
ijpds-3575	1	118	ayush	ayush	VERB
ijpds-3575	1	119	singh	singh	PROPN
ijpds-3575	1	120	,	,	PUNCT
ijpds-3575	1	121	department	department	NOUN
ijpds-3575	1	122	of	of	ADP
ijpds-3575	1	123	production	production	NOUN
ijpds-3575	1	124	,	,	PUNCT
ijpds-3575	1	125	alkem	alkem	PROPN
ijpds-3575	1	126	laboratories	laboratory	NOUN
ijpds-3575	1	127	limited	limit	VERB
ijpds-3575	1	128	,	,	PUNCT
ijpds-3575	1	129	baddi	baddi	PROPN
ijpds-3575	1	130	,	,	PUNCT
ijpds-3575	1	131	solan	solan	PROPN
ijpds-3575	1	132	,	,	PUNCT
ijpds-3575	1	133	himachal	himachal	PROPN
ijpds-3575	1	134	pradesh	pradesh	PROPN
ijpds-3575	1	135	173205	173205	NUM
ijpds-3575	1	136	and	and	CCONJ
ijpds-3575	1	137	department	department	NOUN
ijpds-3575	1	138	of	of	ADP
ijpds-3575	1	139	pharmacy	pharmacy	NOUN
ijpds-3575	1	140	,	,	PUNCT
ijpds-3575	1	141	global	global	ADJ
ijpds-3575	1	142	group	group	NOUN
ijpds-3575	1	143	of	of	ADP
ijpds-3575	1	144	institutes	institutes	PROPN
ijpds-3575	1	145	,	,	PUNCT
ijpds-3575	1	146	amritsar	amritsar	PROPN
ijpds-3575	1	147	,	,	PUNCT
ijpds-3575	1	148	punjab	punjab	ADJ
ijpds-3575	1	149	,	,	PUNCT
ijpds-3575	1	150	india-143501	india-143501	NOUN
ijpds-3575	1	151	.	.	PUNCT
ijpds-3575	2	1	email	email	NOUN
ijpds-3575	2	2	:	:	PUNCT
ijpds-3575	2	3	ayushsingh28659@gmail.com	ayushsingh28659@gmail.com	X
ijpds-3575	3	1	abstract	abstract	ADJ
ijpds-3575	3	2	sars	sar	NOUN
ijpds-3575	3	3	-	-	PUNCT
ijpds-3575	3	4	cov-2	cov-2	NUM
ijpds-3575	3	5	led	lead	VERB
ijpds-3575	3	6	to	to	ADP
ijpds-3575	3	7	several	several	ADJ
ijpds-3575	3	8	unwanted	unwanted	ADJ
ijpds-3575	3	9	deaths	death	NOUN
ijpds-3575	3	10	all	all	ADV
ijpds-3575	3	11	across	across	ADP
ijpds-3575	3	12	the	the	DET
ijpds-3575	3	13	globe	globe	NOUN
ijpds-3575	3	14	since	since	SCONJ
ijpds-3575	3	15	2020	2020	NUM
ijpds-3575	3	16	.	.	PUNCT
ijpds-3575	4	1	high	high	ADJ
ijpds-3575	4	2	mortality	mortality	NOUN
ijpds-3575	4	3	rates	rate	NOUN
ijpds-3575	4	4	are	be	AUX
ijpds-3575	4	5	seen	see	VERB
ijpds-3575	4	6	by	by	ADP
ijpds-3575	4	7	this	this	DET
ijpds-3575	4	8	virus	virus	NOUN
ijpds-3575	4	9	.	.	PUNCT
ijpds-3575	5	1	as	as	ADP
ijpds-3575	5	2	per	per	ADP
ijpds-3575	5	3	the	the	DET
ijpds-3575	5	4	various	various	ADJ
ijpds-3575	5	5	theories	theory	NOUN
ijpds-3575	5	6	,	,	PUNCT
ijpds-3575	5	7	numerous	numerous	ADJ
ijpds-3575	5	8	variant	variant	NOUN
ijpds-3575	5	9	and	and	CCONJ
ijpds-3575	5	10	deadly	deadly	ADJ
ijpds-3575	5	11	strains	strain	NOUN
ijpds-3575	5	12	are	be	AUX
ijpds-3575	5	13	come	come	VERB
ijpds-3575	5	14	into	into	ADP
ijpds-3575	5	15	existence	existence	NOUN
ijpds-3575	5	16	in	in	ADP
ijpds-3575	5	17	the	the	DET
ijpds-3575	5	18	world	world	NOUN
ijpds-3575	5	19	due	due	ADP
ijpds-3575	5	20	to	to	ADP
ijpds-3575	5	21	covid-19	covid-19	PROPN
ijpds-3575	5	22	pandemic	pandemic	NOUN
ijpds-3575	5	23	.	.	PUNCT
ijpds-3575	6	1	to	to	PART
ijpds-3575	6	2	treat	treat	VERB
ijpds-3575	6	3	deadly	deadly	ADJ
ijpds-3575	6	4	strains	strain	NOUN
ijpds-3575	6	5	of	of	ADP
ijpds-3575	6	6	this	this	DET
ijpds-3575	6	7	virus	virus	NOUN
ijpds-3575	6	8	,	,	PUNCT
ijpds-3575	6	9	various	various	ADJ
ijpds-3575	6	10	anti	anti	ADJ
ijpds-3575	6	11	-	-	ADJ
ijpds-3575	6	12	viral	viral	ADJ
ijpds-3575	6	13	are	be	AUX
ijpds-3575	6	14	drugs	drug	NOUN
ijpds-3575	6	15	that	that	PRON
ijpds-3575	6	16	are	be	AUX
ijpds-3575	6	17	utilized	utilize	VERB
ijpds-3575	6	18	in	in	ADP
ijpds-3575	6	19	the	the	DET
ijpds-3575	6	20	therapeutics	therapeutic	NOUN
ijpds-3575	6	21	of	of	ADP
ijpds-3575	6	22	covid-19	covid-19	PROPN
ijpds-3575	6	23	.	.	PUNCT
ijpds-3575	7	1	few	few	ADJ
ijpds-3575	7	2	antivirals	antiviral	NOUN
ijpds-3575	7	3	are	be	AUX
ijpds-3575	7	4	molnupiravir	molnupiravir	PROPN
ijpds-3575	7	5	,	,	PUNCT
ijpds-3575	7	6	favipiravir	favipiravir	PROPN
ijpds-3575	7	7	,	,	PUNCT
ijpds-3575	7	8	remdesivir	remdesivir	PROPN
ijpds-3575	7	9	,	,	PUNCT
ijpds-3575	7	10	alisopirivir	alisopirivir	PROPN
ijpds-3575	7	11	and	and	CCONJ
ijpds-3575	7	12	many	many	ADJ
ijpds-3575	7	13	more	more	ADJ
ijpds-3575	7	14	.	.	PUNCT
ijpds-3575	8	1	molnupiravir	molnupiravir	PROPN
ijpds-3575	8	2	was	be	AUX
ijpds-3575	8	3	originally	originally	ADV
ijpds-3575	8	4	developed	develop	VERB
ijpds-3575	8	5	to	to	PART
ijpds-3575	8	6	treat	treat	VERB
ijpds-3575	8	7	influenza	influenza	NOUN
ijpds-3575	8	8	at	at	ADP
ijpds-3575	8	9	emory	emory	PROPN
ijpds-3575	8	10	university	university	PROPN
ijpds-3575	8	11	but	but	CCONJ
ijpds-3575	8	12	also	also	ADV
ijpds-3575	8	13	reports	report	VERB
ijpds-3575	8	14	abandoned	abandon	VERB
ijpds-3575	8	15	for	for	ADP
ijpds-3575	8	16	mutagenicity	mutagenicity	NOUN
ijpds-3575	8	17	concerns	concern	NOUN
ijpds-3575	8	18	.	.	PUNCT
ijpds-3575	9	1	favipiravir	favipiravir	PROPN
ijpds-3575	9	2	is	be	AUX
ijpds-3575	9	3	a	a	DET
ijpds-3575	9	4	prodrug	prodrug	NOUN
ijpds-3575	9	5	has	have	AUX
ijpds-3575	9	6	been	be	AUX
ijpds-3575	9	7	approved	approve	VERB
ijpds-3575	9	8	to	to	PART
ijpds-3575	9	9	treat	treat	VERB
ijpds-3575	9	10	the	the	DET
ijpds-3575	9	11	influenza	influenza	NOUN
ijpds-3575	9	12	rather	rather	ADV
ijpds-3575	9	13	than	than	ADP
ijpds-3575	9	14	the	the	DET
ijpds-3575	9	15	seasonal	seasonal	ADJ
ijpds-3575	9	16	influenza	influenza	NOUN
ijpds-3575	9	17	and	and	CCONJ
ijpds-3575	9	18	this	this	DET
ijpds-3575	9	19	medication	medication	NOUN
ijpds-3575	9	20	selectively	selectively	ADV
ijpds-3575	9	21	inhibition	inhibition	NOUN
ijpds-3575	9	22	of	of	ADP
ijpds-3575	9	23	rdrp	rdrp	NOUN
ijpds-3575	9	24	.	.	PUNCT
ijpds-3575	10	1	this	this	DET
ijpds-3575	10	2	review	review	NOUN
ijpds-3575	10	3	generally	generally	ADV
ijpds-3575	10	4	covers	cover	VERB
ijpds-3575	10	5	the	the	DET
ijpds-3575	10	6	two	two	NUM
ijpds-3575	10	7	potent	potent	ADJ
ijpds-3575	10	8	oral	oral	ADJ
ijpds-3575	10	9	antiviral	antiviral	ADJ
ijpds-3575	10	10	molnupiravir	molnupiravir	PROPN
ijpds-3575	10	11	and	and	CCONJ
ijpds-3575	10	12	favipiravir	favipiravir	PROPN
ijpds-3575	10	13	investigation	investigation	NOUN
ijpds-3575	10	14	.	.	PUNCT
ijpds-3575	11	1	key	key	ADJ
ijpds-3575	11	2	words	word	NOUN
ijpds-3575	11	3	:	:	PUNCT
ijpds-3575	11	4	molnupiravir	molnupiravir	PROPN
ijpds-3575	11	5	,	,	PUNCT
ijpds-3575	11	6	favipiravir	favipiravir	PROPN
ijpds-3575	11	7	,	,	PUNCT
ijpds-3575	11	8	covid-19	covid-19	PROPN
ijpds-3575	11	9	,	,	PUNCT
ijpds-3575	11	10	sars	sar	NOUN
ijpds-3575	11	11	-	-	PUNCT
ijpds-3575	11	12	cov-2	cov-2	NOUN
ijpds-3575	11	13	,	,	PUNCT
ijpds-3575	11	14	clinical	clinical	ADJ
ijpds-3575	11	15	data	datum	NOUN
ijpds-3575	11	16	,	,	PUNCT
ijpds-3575	11	17	chemical	chemical	PROPN
ijpds-3575	11	18	.	.	PUNCT
ijpds-3575	11	19	oronavirus	oronavirus	PROPN
ijpds-3575	11	20	disease	disease	NOUN
ijpds-3575	11	21	2019	2019	NUM
ijpds-3575	11	22	(	(	PUNCT
ijpds-3575	11	23	covid-19	covid-19	PROPN
ijpds-3575	11	24	)	)	PUNCT
ijpds-3575	11	25	,	,	PUNCT
ijpds-3575	11	26	the	the	DET
ijpds-3575	11	27	illness	illness	NOUN
ijpds-3575	11	28	caused	cause	VERB
ijpds-3575	11	29	by	by	ADP
ijpds-3575	11	30	severe	severe	ADJ
ijpds-3575	11	31	acute	acute	ADJ
ijpds-3575	11	32	respiratory	respiratory	ADJ
ijpds-3575	11	33	syndrome	syndrome	NOUN
ijpds-3575	11	34	coronavirus	coronavirus	NOUN
ijpds-3575	11	35	2	2	NUM
ijpds-3575	11	36	(	(	PUNCT
ijpds-3575	11	37	sars	sar	NOUN
ijpds-3575	11	38	-	-	PUNCT
ijpds-3575	11	39	cov-2	cov-2	NOUN
ijpds-3575	11	40	)	)	PUNCT
ijpds-3575	11	41	,	,	PUNCT
ijpds-3575	11	42	has	have	AUX
ijpds-3575	11	43	had	have	VERB
ijpds-3575	11	44	a	a	DET
ijpds-3575	11	45	devastating	devastating	ADJ
ijpds-3575	11	46	effect	effect	NOUN
ijpds-3575	11	47	on	on	ADP
ijpds-3575	11	48	the	the	DET
ijpds-3575	11	49	world	world	NOUN
ijpds-3575	11	50	’s	’s	PART
ijpds-3575	11	51	population	population	NOUN
ijpds-3575	11	52	resulting	result	VERB
ijpds-3575	11	53	in	in	ADP
ijpds-3575	11	54	more	more	ADJ
ijpds-3575	11	55	than	than	ADP
ijpds-3575	11	56	5.4	5.4	NUM
ijpds-3575	11	57	million	million	NUM
ijpds-3575	11	58	deaths	death	NOUN
ijpds-3575	11	59	worldwide	worldwide	ADV
ijpds-3575	11	60	and	and	CCONJ
ijpds-3575	11	61	emerging	emerge	VERB
ijpds-3575	11	62	as	as	ADP
ijpds-3575	11	63	the	the	DET
ijpds-3575	11	64	most	most	ADV
ijpds-3575	11	65	significant	significant	ADJ
ijpds-3575	11	66	global	global	ADJ
ijpds-3575	11	67	health	health	NOUN
ijpds-3575	11	68	crisis	crisis	NOUN
ijpds-3575	11	69	since	since	SCONJ
ijpds-3575	11	70	the	the	DET
ijpds-3575	11	71	influenza	influenza	NOUN
ijpds-3575	11	72	pandemic	pandemic	ADJ
ijpds-3575	11	73	of	of	ADP
ijpds-3575	11	74	1918	1918	NUM
ijpds-3575	11	75	.	.	PUNCT
ijpds-3575	12	1	since	since	SCONJ
ijpds-3575	12	2	being	be	AUX
ijpds-3575	12	3	declared	declare	VERB
ijpds-3575	12	4	a	a	DET
ijpds-3575	12	5	global	global	ADJ
ijpds-3575	12	6	pandemic	pandemic	NOUN
ijpds-3575	12	7	by	by	ADP
ijpds-3575	12	8	the	the	DET
ijpds-3575	12	9	world	world	PROPN
ijpds-3575	12	10	health	health	PROPN
ijpds-3575	12	11	organization	organization	NOUN
ijpds-3575	12	12	(	(	PUNCT
ijpds-3575	12	13	who	who	PRON
ijpds-3575	12	14	)	)	PUNCT
ijpds-3575	12	15	on	on	ADP
ijpds-3575	12	16	march	march	PROPN
ijpds-3575	12	17	11	11	NUM
ijpds-3575	12	18	,	,	PUNCT
ijpds-3575	12	19	2020	2020	NUM
ijpds-3575	12	20	,	,	PUNCT
ijpds-3575	12	21	the	the	DET
ijpds-3575	12	22	virus	virus	NOUN
ijpds-3575	12	23	continues	continue	VERB
ijpds-3575	12	24	to	to	PART
ijpds-3575	12	25	cause	cause	VERB
ijpds-3575	12	26	devastation	devastation	NOUN
ijpds-3575	12	27	,	,	PUNCT
ijpds-3575	12	28	with	with	ADP
ijpds-3575	12	29	many	many	ADJ
ijpds-3575	12	30	countries	country	NOUN
ijpds-3575	12	31	continuing	continue	VERB
ijpds-3575	12	32	to	to	PART
ijpds-3575	12	33	endure	endure	VERB
ijpds-3575	12	34	multiple	multiple	ADJ
ijpds-3575	12	35	waves	wave	NOUN
ijpds-3575	12	36	of	of	ADP
ijpds-3575	12	37	outbreaks	outbreak	NOUN
ijpds-3575	12	38	of	of	ADP
ijpds-3575	12	39	this	this	DET
ijpds-3575	12	40	viral	viral	ADJ
ijpds-3575	12	41	illness	illness	NOUN
ijpds-3575	12	42	[	[	X
ijpds-3575	12	43	1	1	NUM
ijpds-3575	12	44	]	]	PUNCT
ijpds-3575	12	45	.	.	PUNCT
ijpds-3575	13	1	covid-19	covid-19	PROPN
ijpds-3575	13	2	outbreak	outbreak	NOUN
ijpds-3575	13	3	in	in	ADP
ijpds-3575	13	4	china	china	PROPN
ijpds-3575	13	5	,	,	PUNCT
ijpds-3575	13	6	led	lead	VERB
ijpds-3575	13	7	to	to	ADP
ijpds-3575	13	8	tremendous	tremendous	ADJ
ijpds-3575	13	9	breakdown	breakdown	NOUN
ijpds-3575	13	10	in	in	ADP
ijpds-3575	13	11	the	the	DET
ijpds-3575	13	12	healthcare	healthcare	NOUN
ijpds-3575	13	13	sector	sector	NOUN
ijpds-3575	13	14	.	.	PUNCT
ijpds-3575	14	1	with	with	ADP
ijpds-3575	14	2	emerging	emerge	VERB
ijpds-3575	14	3	therapies	therapy	NOUN
ijpds-3575	14	4	including	include	VERB
ijpds-3575	14	5	vaccines	vaccine	NOUN
ijpds-3575	14	6	and	and	CCONJ
ijpds-3575	14	7	anti	anti	ADJ
ijpds-3575	14	8	-	-	ADJ
ijpds-3575	14	9	viral	viral	ADJ
ijpds-3575	14	10	therapies	therapy	NOUN
ijpds-3575	14	11	,	,	PUNCT
ijpds-3575	14	12	it	it	PRON
ijpds-3575	14	13	is	be	AUX
ijpds-3575	14	14	necessary	necessary	ADJ
ijpds-3575	14	15	to	to	PART
ijpds-3575	14	16	research	research	VERB
ijpds-3575	14	17	on	on	ADP
ijpds-3575	14	18	their	their	PRON
ijpds-3575	14	19	clinical	clinical	ADJ
ijpds-3575	14	20	effects	effect	NOUN
ijpds-3575	14	21	on	on	ADP
ijpds-3575	14	22	treatment	treatment	NOUN
ijpds-3575	14	23	.	.	PUNCT
ijpds-3575	15	1	most	most	ADJ
ijpds-3575	15	2	of	of	ADP
ijpds-3575	15	3	the	the	DET
ijpds-3575	15	4	drugs	drug	NOUN
ijpds-3575	15	5	used	use	VERB
ijpds-3575	15	6	in	in	ADP
ijpds-3575	15	7	clinical	clinical	ADJ
ijpds-3575	15	8	practice	practice	NOUN
ijpds-3575	15	9	have	have	AUX
ijpds-3575	15	10	limited	limit	VERB
ijpds-3575	15	11	clinical	clinical	ADJ
ijpds-3575	15	12	experience	experience	NOUN
ijpds-3575	15	13	[	[	X
ijpds-3575	15	14	2	2	NUM
ijpds-3575	15	15	]	]	PUNCT
ijpds-3575	15	16	.	.	PUNCT
ijpds-3575	16	1	with	with	ADP
ijpds-3575	16	2	the	the	DET
ijpds-3575	16	3	vast	vast	ADJ
ijpds-3575	16	4	expanding	expand	VERB
ijpds-3575	16	5	knowledge	knowledge	NOUN
ijpds-3575	16	6	of	of	ADP
ijpds-3575	16	7	the	the	DET
ijpds-3575	16	8	sars	sar	NOUN
ijpds-3575	16	9	-	-	PUNCT
ijpds-3575	16	10	cov-2	cov-2	NOUN
ijpds-3575	16	11	virology	virology	NOUN
ijpds-3575	16	12	,	,	PUNCT
ijpds-3575	16	13	newer	new	ADJ
ijpds-3575	16	14	potential	potential	ADJ
ijpds-3575	16	15	targets	target	NOUN
ijpds-3575	16	16	are	be	AUX
ijpds-3575	16	17	being	be	AUX
ijpds-3575	16	18	identified	identify	VERB
ijpds-3575	16	19	.	.	PUNCT
ijpds-3575	17	1	we	we	PRON
ijpds-3575	17	2	have	have	AUX
ijpds-3575	17	3	summarized	summarize	VERB
ijpds-3575	17	4	the	the	DET
ijpds-3575	17	5	clinical	clinical	ADJ
ijpds-3575	17	6	picture	picture	NOUN
ijpds-3575	17	7	of	of	ADP
ijpds-3575	17	8	two	two	NUM
ijpds-3575	17	9	anti	anti	ADJ
ijpds-3575	17	10	-	-	ADJ
ijpds-3575	17	11	virals	viral	NOUN
ijpds-3575	17	12	molnuoiravir	molnuoiravir	NOUN
ijpds-3575	17	13	and	and	CCONJ
ijpds-3575	17	14	favipiravir	favipiravir	PROPN
ijpds-3575	17	15	.	.	PUNCT
ijpds-3575	18	1	molunipiravir	molunipiravir	NOUN
ijpds-3575	18	2	is	be	AUX
ijpds-3575	18	3	the	the	DET
ijpds-3575	18	4	first	first	ADJ
ijpds-3575	18	5	oral	oral	ADJ
ijpds-3575	18	6	antiviral	antiviral	ADJ
ijpds-3575	18	7	medicine	medicine	NOUN
ijpds-3575	18	8	to	to	PART
ijpds-3575	18	9	show	show	VERB
ijpds-3575	18	10	considerable	considerable	ADJ
ijpds-3575	18	11	and	and	CCONJ
ijpds-3575	18	12	convincing	convincing	ADJ
ijpds-3575	18	13	antiviral	antiviral	ADJ
ijpds-3575	18	14	activity	activity	NOUN
ijpds-3575	18	15	in	in	ADP
ijpds-3575	18	16	vitro	vitro	X
ijpds-3575	18	17	and	and	CCONJ
ijpds-3575	18	18	in	in	ADP
ijpds-3575	18	19	animal	animal	NOUN
ijpds-3575	18	20	models	model	NOUN
ijpds-3575	18	21	.	.	PUNCT
ijpds-3575	19	1	shreds	shred	NOUN
ijpds-3575	19	2	of	of	ADP
ijpds-3575	19	3	evidence	evidence	NOUN
ijpds-3575	19	4	suggest	suggest	VERB
ijpds-3575	19	5	that	that	SCONJ
ijpds-3575	19	6	molnupiravir	molnupiravir	PROPN
ijpds-3575	19	7	reduces	reduce	VERB
ijpds-3575	19	8	hospitalization	hospitalization	NOUN
ijpds-3575	19	9	and	and	CCONJ
ijpds-3575	19	10	mortality	mortality	NOUN
ijpds-3575	19	11	among	among	ADP
ijpds-3575	19	12	unvaccinated	unvaccinated	ADJ
ijpds-3575	19	13	individuals	individual	NOUN
ijpds-3575	19	14	[	[	X
ijpds-3575	19	15	3	3	NUM
ijpds-3575	19	16	]	]	PUNCT
ijpds-3575	19	17	.	.	PUNCT
ijpds-3575	20	1	favipiravir	favipiravir	PROPN
ijpds-3575	20	2	is	be	AUX
ijpds-3575	20	3	also	also	ADV
ijpds-3575	20	4	one	one	NUM
ijpds-3575	20	5	such	such	ADJ
ijpds-3575	20	6	drug	drug	NOUN
ijpds-3575	20	7	with	with	ADP
ijpds-3575	20	8	a	a	DET
ijpds-3575	20	9	crucial	crucial	ADJ
ijpds-3575	20	10	role	role	NOUN
ijpds-3575	20	11	in	in	ADP
ijpds-3575	20	12	treating	treat	VERB
ijpds-3575	20	13	mild	mild	NOUN
ijpds-3575	20	14	to	to	ADP
ijpds-3575	20	15	moderate	moderate	ADJ
ijpds-3575	20	16	covid-19	covid-19	PROPN
ijpds-3575	20	17	.	.	PUNCT
ijpds-3575	21	1	with	with	ADP
ijpds-3575	21	2	its	its	PRON
ijpds-3575	21	3	oral	oral	ADJ
ijpds-3575	21	4	form	form	NOUN
ijpds-3575	21	5	it	it	PRON
ijpds-3575	21	6	can	can	AUX
ijpds-3575	21	7	be	be	AUX
ijpds-3575	21	8	easily	easily	ADV
ijpds-3575	21	9	administered	administer	VERB
ijpds-3575	21	10	and	and	CCONJ
ijpds-3575	21	11	meant	mean	VERB
ijpds-3575	21	12	for	for	ADP
ijpds-3575	21	13	treatment	treatment	NOUN
ijpds-3575	21	14	in	in	ADP
ijpds-3575	21	15	mildly	mildly	ADV
ijpds-3575	21	16	ill	ill	ADJ
ijpds-3575	21	17	covid-19	covid-19	PROPN
ijpds-3575	21	18	patients	patient	NOUN
ijpds-3575	21	19	[	[	X
ijpds-3575	21	20	4	4	NUM
ijpds-3575	21	21	]	]	PUNCT
ijpds-3575	21	22	.	.	PUNCT
ijpds-3575	22	1	variants	variant	NOUN
ijpds-3575	22	2	of	of	ADP
ijpds-3575	22	3	sars	sar	NOUN
ijpds-3575	22	4	-	-	PUNCT
ijpds-3575	22	5	cov-2	cov-2	PART
ijpds-3575	22	6	since	since	SCONJ
ijpds-3575	22	7	the	the	DET
ijpds-3575	22	8	covid-19	covid-19	PROPN
ijpds-3575	22	9	pandemic	pandemic	NOUN
ijpds-3575	22	10	first	first	ADV
ijpds-3575	22	11	began	begin	VERB
ijpds-3575	22	12	in	in	ADP
ijpds-3575	22	13	december	december	PROPN
ijpds-3575	22	14	2019	2019	NUM
ijpds-3575	22	15	,	,	PUNCT
ijpds-3575	22	16	the	the	DET
ijpds-3575	22	17	severe	severe	ADJ
ijpds-3575	22	18	acute	acute	ADJ
ijpds-3575	22	19	respiratory	respiratory	ADJ
ijpds-3575	22	20	syndrome	syndrome	NOUN
ijpds-3575	22	21	coronavirus	coronavirus	NOUN
ijpds-3575	22	22	2	2	NUM
ijpds-3575	22	23	(	(	PUNCT
ijpds-3575	22	24	sarscov-2	sarscov-2	NUM
ijpds-3575	22	25	)	)	PUNCT
ijpds-3575	22	26	virus	virus	NOUN
ijpds-3575	22	27	has	have	AUX
ijpds-3575	22	28	continuously	continuously	ADV
ijpds-3575	22	29	evolved	evolve	VERB
ijpds-3575	22	30	with	with	ADP
ijpds-3575	22	31	many	many	ADJ
ijpds-3575	22	32	variants	variant	NOUN
ijpds-3575	22	33	emerging	emerge	VERB
ijpds-3575	22	34	across	across	ADP
ijpds-3575	22	35	the	the	DET
ijpds-3575	22	36	world	world	NOUN
ijpds-3575	22	37	.	.	PUNCT
ijpds-3575	23	1	these	these	DET
ijpds-3575	23	2	variants	variant	NOUN
ijpds-3575	23	3	are	be	AUX
ijpds-3575	23	4	categorized	categorize	VERB
ijpds-3575	23	5	as	as	ADP
ijpds-3575	23	6	the	the	DET
ijpds-3575	23	7	variant	variant	NOUN
ijpds-3575	23	8	of	of	ADP
ijpds-3575	23	9	interest	interest	NOUN
ijpds-3575	23	10	(	(	PUNCT
ijpds-3575	23	11	voi	voi	NOUN
ijpds-3575	23	12	)	)	PUNCT
ijpds-3575	23	13	,	,	PUNCT
ijpds-3575	23	14	variant	variant	NOUN
ijpds-3575	23	15	of	of	ADP
ijpds-3575	23	16	concern	concern	NOUN
ijpds-3575	23	17	(	(	PUNCT
ijpds-3575	23	18	voc	voc	NOUN
ijpds-3575	23	19	)	)	PUNCT
ijpds-3575	23	20	,	,	PUNCT
ijpds-3575	23	21	and	and	CCONJ
ijpds-3575	23	22	variant	variant	NOUN
ijpds-3575	23	23	under	under	ADP
ijpds-3575	23	24	monitoring	monitoring	NOUN
ijpds-3575	23	25	(	(	PUNCT
ijpds-3575	23	26	vum	vum	PROPN
ijpds-3575	23	27	)	)	PUNCT
ijpds-3575	23	28	.	.	PUNCT
ijpds-3575	24	1	as	as	ADP
ijpds-3575	24	2	of	of	ADP
ijpds-3575	24	3	september	september	PROPN
ijpds-3575	24	4	15	15	NUM
ijpds-3575	24	5	,	,	PUNCT
ijpds-3575	24	6	2021	2021	NUM
ijpds-3575	24	7	,	,	PUNCT
ijpds-3575	24	8	there	there	PRON
ijpds-3575	24	9	are	be	VERB
ijpds-3575	24	10	four	four	NUM
ijpds-3575	24	11	sars	sar	NOUN
ijpds-3575	24	12	-	-	PUNCT
ijpds-3575	24	13	cov-2	cov-2	PART
ijpds-3575	24	14	lineages	lineage	NOUN
ijpds-3575	24	15	designated	designate	VERB
ijpds-3575	24	16	as	as	ADP
ijpds-3575	24	17	the	the	DET
ijpds-3575	24	18	voc	voc	NOUN
ijpds-3575	24	19	(	(	PUNCT
ijpds-3575	24	20	alpha	alpha	NOUN
ijpds-3575	24	21	,	,	PUNCT
ijpds-3575	24	22	beta	beta	NOUN
ijpds-3575	24	23	,	,	PUNCT
ijpds-3575	24	24	gamma	gamma	NOUN
ijpds-3575	24	25	,	,	PUNCT
ijpds-3575	24	26	and	and	CCONJ
ijpds-3575	24	27	delta	delta	NOUN
ijpds-3575	24	28	variants	variant	NOUN
ijpds-3575	24	29	)	)	PUNCT
ijpds-3575	24	30	.	.	PUNCT
ijpds-3575	25	1	vocs	vocs	PROPN
ijpds-3575	25	2	have	have	AUX
ijpds-3575	25	3	increased	increase	VERB
ijpds-3575	25	4	transmissibility	transmissibility	NOUN
ijpds-3575	25	5	compared	compare	VERB
ijpds-3575	25	6	to	to	ADP
ijpds-3575	25	7	the	the	DET
ijpds-3575	25	8	original	original	ADJ
ijpds-3575	25	9	virus	virus	NOUN
ijpds-3575	25	10	,	,	PUNCT
ijpds-3575	25	11	and	and	CCONJ
ijpds-3575	25	12	have	have	VERB
ijpds-3575	25	13	the	the	DET
ijpds-3575	25	14	potential	potential	NOUN
ijpds-3575	25	15	for	for	ADP
ijpds-3575	25	16	increasing	increase	VERB
ijpds-3575	25	17	disease	disease	NOUN
ijpds-3575	25	18	severity	severity	NOUN
ijpds-3575	25	19	[	[	X
ijpds-3575	25	20	5	5	NUM
ijpds-3575	25	21	]	]	PUNCT
ijpds-3575	25	22	.	.	PUNCT
ijpds-3575	26	1	all	all	DET
ijpds-3575	26	2	the	the	DET
ijpds-3575	26	3	variant	variant	NOUN
ijpds-3575	26	4	of	of	ADP
ijpds-3575	26	5	sarscov-2	sarscov-2	NUM
ijpds-3575	26	6	are	be	AUX
ijpds-3575	26	7	enlisted	enlist	VERB
ijpds-3575	26	8	in	in	ADP
ijpds-3575	26	9	the	the	DET
ijpds-3575	26	10	table	table	NOUN
ijpds-3575	26	11	no	no	INTJ
ijpds-3575	26	12	.	.	NOUN
ijpds-3575	27	1	1	1	X
ijpds-3575	27	2	.	.	X
ijpds-3575	28	1	molnupiravir	molnupiravir	PROPN
ijpds-3575	28	2	molnupiravir	molnupiravir	PROPN
ijpds-3575	28	3	is	be	AUX
ijpds-3575	28	4	the	the	DET
ijpds-3575	28	5	drug	drug	NOUN
ijpds-3575	28	6	that	that	PRON
ijpds-3575	28	7	came	come	VERB
ijpds-3575	28	8	into	into	ADP
ijpds-3575	28	9	existence	existence	NOUN
ijpds-3575	28	10	worldwide	worldwide	ADV
ijpds-3575	28	11	for	for	ADP
ijpds-3575	28	12	the	the	DET
ijpds-3575	28	13	treatment	treatment	NOUN
ijpds-3575	28	14	of	of	ADP
ijpds-3575	28	15	covid-19	covid-19	PROPN
ijpds-3575	28	16	.	.	PUNCT
ijpds-3575	29	1	molnupiravir	molnupiravir	PROPN
ijpds-3575	29	2	(	(	PUNCT
ijpds-3575	29	3	emory	emory	PROPN
ijpds-3575	29	4	institute	institute	PROPN
ijpds-3575	29	5	of	of	ADP
ijpds-3575	29	6	drug	drug	NOUN
ijpds-3575	29	7	development-2801	development-2801	NOUN
ijpds-3575	29	8	[	[	X
ijpds-3575	29	9	eidd-2801]/mk-4482	eidd-2801]/mk-4482	PROPN
ijpds-3575	29	10	)	)	PUNCT
ijpds-3575	29	11	is	be	AUX
ijpds-3575	29	12	one	one	NUM
ijpds-3575	29	13	of	of	ADP
ijpds-3575	29	14	the	the	DET
ijpds-3575	29	15	upcoming	upcoming	ADJ
ijpds-3575	29	16	oral	oral	ADJ
ijpds-3575	29	17	drugs	drug	NOUN
ijpds-3575	29	18	which	which	PRON
ijpds-3575	29	19	is	be	AUX
ijpds-3575	29	20	promising	promise	VERB
ijpds-3575	29	21	.	.	PUNCT
ijpds-3575	30	1	this	this	DET
ijpds-3575	30	2	oral	oral	ADJ
ijpds-3575	30	3	agent	agent	NOUN
ijpds-3575	30	4	was	be	AUX
ijpds-3575	30	5	developed	develop	VERB
ijpds-3575	30	6	by	by	ADP
ijpds-3575	30	7	drug	drug	NOUN
ijpds-3575	30	8	innovation	innovation	NOUN
ijpds-3575	30	9	ventures	venture	NOUN
ijpds-3575	30	10	at	at	ADP
ijpds-3575	30	11	emory	emory	PROPN
ijpds-3575	30	12	university	university	PROPN
ijpds-3575	30	13	,	,	PUNCT
ijpds-3575	30	14	and	and	CCONJ
ijpds-3575	30	15	later	later	ADV
ijpds-3575	30	16	acquired	acquire	VERB
ijpds-3575	30	17	by	by	ADP
ijpds-3575	30	18	ridgeback	ridgeback	NOUN
ijpds-3575	30	19	therapeutics	therapeutic	NOUN
ijpds-3575	30	20	in	in	ADP
ijpds-3575	30	21	partnershipwith	partnershipwith	PROPN
ijpds-3575	30	22	merck	merck	PROPN
ijpds-3575	30	23	&	&	CCONJ
ijpds-3575	30	24	co	co	PROPN
ijpds-3575	30	25	,	,	PUNCT
ijpds-3575	30	26	usa	usa	PROPN
ijpds-3575	30	27	.	.	PROPN
ijpds-3575	30	28	in	in	ADP
ijpds-3575	30	29	general	general	ADJ
ijpds-3575	30	30	,	,	PUNCT
ijpds-3575	30	31	antiviral	antiviral	ADJ
ijpds-3575	30	32	drugs	drug	NOUN
ijpds-3575	30	33	tested	test	VERB
ijpds-3575	30	34	so	so	ADV
ijpds-3575	30	35	far	far	ADV
ijpds-3575	30	36	usually	usually	ADV
ijpds-3575	30	37	terminate	terminate	VERB
ijpds-3575	30	38	the	the	DET
ijpds-3575	30	39	elongation	elongation	NOUN
ijpds-3575	30	40	of	of	ADP
ijpds-3575	30	41	rna	rna	NOUN
ijpds-3575	30	42	-	-	PUNCT
ijpds-3575	30	43	chain	chain	NOUN
ijpds-3575	30	44	by	by	ADP
ijpds-3575	30	45	targeting	target	VERB
ijpds-3575	30	46	the	the	DET
ijpds-3575	30	47	viral	viral	ADJ
ijpds-3575	30	48	polymerases	polymerase	NOUN
ijpds-3575	30	49	but	but	CCONJ
ijpds-3575	30	50	such	such	ADJ
ijpds-3575	30	51	anti	anti	NOUN
ijpds-3575	30	52	-	-	NOUN
ijpds-3575	30	53	virals	viral	NOUN
ijpds-3575	30	54	have	have	AUX
ijpds-3575	30	55	not	not	PART
ijpds-3575	30	56	shown	show	VERB
ijpds-3575	30	57	a	a	DET
ijpds-3575	30	58	very	very	ADV
ijpds-3575	30	59	promising	promising	ADJ
ijpds-3575	30	60	role	role	NOUN
ijpds-3575	30	61	in	in	ADP
ijpds-3575	30	62	the	the	DET
ijpds-3575	30	63	treatment	treatment	NOUN
ijpds-3575	30	64	of	of	ADP
ijpds-3575	30	65	sars	sar	NOUN
ijpds-3575	30	66	-	-	PUNCT
ijpds-3575	30	67	cov-2	cov-2	NOUN
ijpds-3575	30	68	c	c	PROPN
ijpds-3575	30	69	singh	singh	PROPN
ijpds-3575	30	70	et	et	PROPN
ijpds-3575	30	71	al	al	PROPN
ijpds-3575	30	72	.	.	PROPN
ijpds-3575	30	73	molnupiravir	molnupiravir	PROPN
ijpds-3575	30	74	and	and	CCONJ
ijpds-3575	30	75	favipiravir	favipiravir	PROPN
ijpds-3575	30	76	in	in	ADP
ijpds-3575	30	77	sars	sars	PROPN
ijpds-3575	30	78	-	-	PUNCT
ijpds-3575	30	79	cov-2	cov-2	PART
ijpds-3575	30	80	vol	vol	NOUN
ijpds-3575	30	81	1	1	NUM
ijpds-3575	30	82	|	|	ADV
ijpds-3575	30	83	issue	issue	VERB
ijpds-3575	30	84	3	3	NUM
ijpds-3575	30	85	|	|	ADV
ijpds-3575	30	86	oct	oct	PROPN
ijpds-3575	30	87	dec	dec	PROPN
ijpds-3575	30	88	2022	2022	NUM
ijpds-3575	30	89	indian	indian	PROPN
ijpds-3575	30	90	j	j	PROPN
ijpds-3575	30	91	pharm	pharm	PROPN
ijpds-3575	30	92	drug	drug	PROPN
ijpds-3575	30	93	studies	study	NOUN
ijpds-3575	30	94	|	|	ADV
ijpds-3575	30	95	74	74	NUM
ijpds-3575	30	96	infections	infection	NOUN
ijpds-3575	30	97	[	[	X
ijpds-3575	30	98	14	14	NUM
ijpds-3575	30	99	]	]	PUNCT
ijpds-3575	30	100	.	.	PUNCT
ijpds-3575	31	1	this	this	DET
ijpds-3575	31	2	drug	drug	NOUN
ijpds-3575	31	3	affects	affect	VERB
ijpds-3575	31	4	the	the	DET
ijpds-3575	31	5	rna	rna	NOUN
ijpds-3575	31	6	-	-	PUNCT
ijpds-3575	31	7	dependent	dependent	ADJ
ijpds-3575	31	8	rnapolymerase	rnapolymerase	NOUN
ijpds-3575	31	9	enzyme	enzyme	NOUN
ijpds-3575	31	10	used	use	VERB
ijpds-3575	31	11	by	by	ADP
ijpds-3575	31	12	the	the	DET
ijpds-3575	31	13	coronavirus	coronavirus	NOUN
ijpds-3575	31	14	for	for	ADP
ijpds-3575	31	15	transcription	transcription	NOUN
ijpds-3575	31	16	and	and	CCONJ
ijpds-3575	31	17	replication	replication	NOUN
ijpds-3575	31	18	of	of	ADP
ijpds-3575	31	19	its	its	PRON
ijpds-3575	31	20	viral	viral	ADJ
ijpds-3575	31	21	rna	rna	NOUN
ijpds-3575	31	22	genome	genome	NOUN
ijpds-3575	31	23	[	[	X
ijpds-3575	31	24	15	15	NUM
ijpds-3575	31	25	]	]	PUNCT
ijpds-3575	31	26	.	.	PUNCT
ijpds-3575	32	1	figure	figure	NOUN
ijpds-3575	32	2	1	1	NUM
ijpds-3575	32	3	:	:	PUNCT
ijpds-3575	32	4	chemical	chemical	ADJ
ijpds-3575	32	5	structure	structure	NOUN
ijpds-3575	32	6	of	of	ADP
ijpds-3575	32	7	molnupiravir	molnupiravir	PROPN
ijpds-3575	32	8	molnupiravir	molnupiravir	PROPN
ijpds-3575	32	9	is	be	AUX
ijpds-3575	32	10	an	an	DET
ijpds-3575	32	11	isopropyl	isopropyl	NOUN
ijpds-3575	32	12	ester	ester	NOUN
ijpds-3575	32	13	prodrug	prodrug	NOUN
ijpds-3575	32	14	of	of	ADP
ijpds-3575	32	15	the	the	DET
ijpds-3575	32	16	nucleoside	nucleoside	ADJ
ijpds-3575	32	17	analogue	analogue	NOUN
ijpds-3575	32	18	β	β	NOUN
ijpds-3575	32	19	-	-	ADJ
ijpds-3575	32	20	d	d	PROPN
ijpds-3575	32	21	-	-	PUNCT
ijpds-3575	32	22	n4	n4	ADJ
ijpds-3575	32	23	–	–	PUNCT
ijpds-3575	32	24	hydroxycytidine	hydroxycytidine	PROPN
ijpds-3575	32	25	(	(	PUNCT
ijpds-3575	32	26	nhc	nhc	NOUN
ijpds-3575	32	27	or	or	CCONJ
ijpds-3575	32	28	eidd-1931	eidd-1931	ADJ
ijpds-3575	32	29	)	)	PUNCT
ijpds-3575	32	30	.	.	PUNCT
ijpds-3575	33	1	molnupiravir	molnupiravir	PROPN
ijpds-3575	33	2	interferes	interfere	VERB
ijpds-3575	33	3	with	with	ADP
ijpds-3575	33	4	the	the	DET
ijpds-3575	33	5	replication	replication	NOUN
ijpds-3575	33	6	of	of	ADP
ijpds-3575	33	7	various	various	ADJ
ijpds-3575	33	8	viruses	virus	NOUN
ijpds-3575	33	9	,	,	PUNCT
ijpds-3575	33	10	including	include	VERB
ijpds-3575	33	11	sars	sar	NOUN
ijpds-3575	33	12	-	-	PUNCT
ijpds-3575	33	13	cov-2	cov-2	NOUN
ijpds-3575	33	14	.	.	PUNCT
ijpds-3575	34	1	it	it	PRON
ijpds-3575	34	2	inhibits	inhibit	VERB
ijpds-3575	34	3	sars	sar	NOUN
ijpds-3575	34	4	-	-	PUNCT
ijpds-3575	34	5	cov-2	cov-2	NOUN
ijpds-3575	34	6	replication	replication	NOUN
ijpds-3575	34	7	in	in	ADP
ijpds-3575	34	8	human	human	ADJ
ijpds-3575	34	9	lung	lung	NOUN
ijpds-3575	34	10	tissue	tissue	NOUN
ijpds-3575	34	11	,	,	PUNCT
ijpds-3575	34	12	blocks	block	VERB
ijpds-3575	34	13	sars	sar	NOUN
ijpds-3575	34	14	-	-	PUNCT
ijpds-3575	34	15	cov-2	cov-2	NOUN
ijpds-3575	34	16	transmission	transmission	NOUN
ijpds-3575	34	17	in	in	ADP
ijpds-3575	34	18	ferrets	ferret	NOUN
ijpds-3575	34	19	and	and	CCONJ
ijpds-3575	34	20	reduces	reduce	VERB
ijpds-3575	34	21	sars	sar	NOUN
ijpds-3575	34	22	-	-	PUNCT
ijpds-3575	34	23	cov-2	cov-2	NOUN
ijpds-3575	34	24	rna	rna	NOUN
ijpds-3575	34	25	in	in	ADP
ijpds-3575	34	26	patients	patient	NOUN
ijpds-3575	34	27	[	[	X
ijpds-3575	34	28	15].it	15].it	NUM
ijpds-3575	34	29	is	be	AUX
ijpds-3575	34	30	β	β	NOUN
ijpds-3575	34	31	-	-	ADJ
ijpds-3575	34	32	d	d	NOUN
ijpds-3575	34	33	-	-	ADJ
ijpds-3575	34	34	n4hydroxycytidine	n4hydroxycytidine	ADJ
ijpds-3575	34	35	(	(	PUNCT
ijpds-3575	34	36	eidd-1931	eidd-1931	ADJ
ijpds-3575	34	37	)	)	PUNCT
ijpds-3575	34	38	is	be	AUX
ijpds-3575	34	39	an	an	DET
ijpds-3575	34	40	orally	orally	ADV
ijpds-3575	34	41	bioavailable	bioavailable	ADJ
ijpds-3575	34	42	ribonucleoside	ribonucleoside	NOUN
ijpds-3575	34	43	analogue	analogue	NOUN
ijpds-3575	34	44	and	and	CCONJ
ijpds-3575	34	45	has	have	VERB
ijpds-3575	34	46	broad	broad	ADJ
ijpds-3575	34	47	-	-	PUNCT
ijpds-3575	34	48	spectrum	spectrum	NOUN
ijpds-3575	34	49	activity	activity	NOUN
ijpds-3575	34	50	against	against	ADP
ijpds-3575	34	51	numerous	numerous	ADJ
ijpds-3575	34	52	rna	rna	NOUN
ijpds-3575	34	53	viruses	virus	NOUN
ijpds-3575	34	54	in	in	ADP
ijpds-3575	34	55	animal	animal	NOUN
ijpds-3575	34	56	models	model	NOUN
ijpds-3575	35	1	[	[	X
ijpds-3575	35	2	16	16	NUM
ijpds-3575	35	3	-	-	SYM
ijpds-3575	35	4	18	18	NUM
ijpds-3575	35	5	]	]	PUNCT
ijpds-3575	35	6	.	.	PUNCT
ijpds-3575	36	1	molnupiravir	molnupiravir	PROPN
ijpds-3575	36	2	(	(	PUNCT
ijpds-3575	36	3	eidd-2801	eidd-2801	NOUN
ijpds-3575	36	4	)	)	PUNCT
ijpds-3575	36	5	,	,	PUNCT
ijpds-3575	36	6	is	be	AUX
ijpds-3575	36	7	a	a	DET
ijpds-3575	36	8	prodrug	prodrug	NOUN
ijpds-3575	36	9	of	of	ADP
ijpds-3575	36	10	β	β	NOUN
ijpds-3575	36	11	-	-	ADJ
ijpds-3575	36	12	d	d	NOUN
ijpds-3575	36	13	-	-	ADJ
ijpds-3575	36	14	n4hydroxycytidine	n4hydroxycytidine	ADJ
ijpds-3575	36	15	(	(	PUNCT
ijpds-3575	36	16	eidd-1931	eidd-1931	ADJ
ijpds-3575	36	17	)	)	PUNCT
ijpds-3575	36	18	and	and	CCONJ
ijpds-3575	36	19	is	be	AUX
ijpds-3575	36	20	rapidly	rapidly	ADV
ijpds-3575	36	21	converted	convert	VERB
ijpds-3575	36	22	into	into	ADP
ijpds-3575	36	23	eidd-1931	eidd-1931	ADJ
ijpds-3575	36	24	in	in	ADP
ijpds-3575	36	25	the	the	DET
ijpds-3575	36	26	plasma	plasma	NOUN
ijpds-3575	36	27	by	by	ADP
ijpds-3575	36	28	the	the	DET
ijpds-3575	36	29	host	host	NOUN
ijpds-3575	36	30	’s	’s	PART
ijpds-3575	36	31	esterase	esterase	NOUN
ijpds-3575	36	32	.	.	PUNCT
ijpds-3575	37	1	after	after	ADP
ijpds-3575	37	2	entering	enter	VERB
ijpds-3575	37	3	host	host	NOUN
ijpds-3575	37	4	cells	cell	NOUN
ijpds-3575	37	5	,	,	PUNCT
ijpds-3575	37	6	eidd-1931	eidd-1931	ADJ
ijpds-3575	37	7	is	be	AUX
ijpds-3575	37	8	intracellularly	intracellularly	ADV
ijpds-3575	37	9	transformed	transform	VERB
ijpds-3575	37	10	into	into	ADP
ijpds-3575	37	11	its	its	PRON
ijpds-3575	37	12	active	active	ADJ
ijpds-3575	37	13	form	form	NOUN
ijpds-3575	37	14	,	,	PUNCT
ijpds-3575	37	15	β	β	NOUN
ijpds-3575	37	16	-	-	ADJ
ijpds-3575	37	17	d	d	PROPN
ijpds-3575	37	18	-	-	PUNCT
ijpds-3575	37	19	n4	n4	PROPN
ijpds-3575	37	20	-	-	PUNCT
ijpds-3575	37	21	hydroxycytidine	hydroxycytidine	NOUN
ijpds-3575	37	22	-	-	PUNCT
ijpds-3575	37	23	triphosphate	triphosphate	NOUN
ijpds-3575	37	24	,	,	PUNCT
ijpds-3575	37	25	which	which	PRON
ijpds-3575	37	26	inhibits	inhibit	VERB
ijpds-3575	37	27	viral	viral	ADJ
ijpds-3575	37	28	replication	replication	NOUN
ijpds-3575	37	29	through	through	ADP
ijpds-3575	37	30	its	its	PRON
ijpds-3575	37	31	incorporation	incorporation	NOUN
ijpds-3575	37	32	into	into	ADP
ijpds-3575	37	33	the	the	DET
ijpds-3575	37	34	viral	viral	ADJ
ijpds-3575	37	35	genome	genome	NOUN
ijpds-3575	37	36	.	.	PUNCT
ijpds-3575	38	1	consequently	consequently	ADV
ijpds-3575	38	2	,	,	PUNCT
ijpds-3575	38	3	the	the	DET
ijpds-3575	38	4	accumulation	accumulation	NOUN
ijpds-3575	38	5	of	of	ADP
ijpds-3575	38	6	mutations	mutation	NOUN
ijpds-3575	38	7	results	result	VERB
ijpds-3575	38	8	in	in	ADP
ijpds-3575	38	9	the	the	DET
ijpds-3575	38	10	viral	viral	ADJ
ijpds-3575	38	11	error	error	NOUN
ijpds-3575	38	12	catastrophe	catastrophe	NOUN
ijpds-3575	38	13	.	.	PUNCT
ijpds-3575	39	1	mechanism	mechanism	NOUN
ijpds-3575	39	2	of	of	ADP
ijpds-3575	39	3	action	action	NOUN
ijpds-3575	39	4	previously	previously	ADV
ijpds-3575	39	5	,	,	PUNCT
ijpds-3575	39	6	it	it	PRON
ijpds-3575	39	7	was	be	AUX
ijpds-3575	39	8	developed	develop	VERB
ijpds-3575	39	9	to	to	PART
ijpds-3575	39	10	treat	treat	VERB
ijpds-3575	39	11	influenza	influenza	NOUN
ijpds-3575	39	12	and	and	CCONJ
ijpds-3575	39	13	was	be	AUX
ijpds-3575	39	14	recognized	recognize	VERB
ijpds-3575	39	15	as	as	ADP
ijpds-3575	39	16	another	another	DET
ijpds-3575	39	17	candidate	candidate	NOUN
ijpds-3575	39	18	for	for	ADP
ijpds-3575	39	19	antiviral	antiviral	ADJ
ijpds-3575	39	20	drugs	drug	NOUN
ijpds-3575	39	21	.	.	PUNCT
ijpds-3575	40	1	understanding	understand	VERB
ijpds-3575	40	2	the	the	DET
ijpds-3575	40	3	mechanism	mechanism	NOUN
ijpds-3575	40	4	of	of	ADP
ijpds-3575	40	5	molnupiravir	molnupiravir	PROPN
ijpds-3575	40	6	at	at	ADP
ijpds-3575	40	7	the	the	DET
ijpds-3575	40	8	molecular	molecular	ADJ
ijpds-3575	40	9	level	level	NOUN
ijpds-3575	40	10	is	be	AUX
ijpds-3575	40	11	critical	critical	ADJ
ijpds-3575	40	12	to	to	ADP
ijpds-3575	40	13	the	the	DET
ijpds-3575	40	14	further	further	ADJ
ijpds-3575	40	15	development	development	NOUN
ijpds-3575	40	16	of	of	ADP
ijpds-3575	40	17	antiviral	antiviral	ADJ
ijpds-3575	40	18	drugs	drug	NOUN
ijpds-3575	40	19	.	.	PUNCT
ijpds-3575	41	1	the	the	DET
ijpds-3575	41	2	drug	drug	NOUN
ijpds-3575	41	3	is	be	AUX
ijpds-3575	41	4	activated	activate	VERB
ijpds-3575	41	5	through	through	ADP
ijpds-3575	41	6	metabolism	metabolism	NOUN
ijpds-3575	41	7	in	in	ADP
ijpds-3575	41	8	the	the	DET
ijpds-3575	41	9	body	body	NOUN
ijpds-3575	41	10	.	.	PUNCT
ijpds-3575	42	1	once	once	ADV
ijpds-3575	42	2	inside	inside	ADP
ijpds-3575	42	3	the	the	DET
ijpds-3575	42	4	cell	cell	NOUN
ijpds-3575	42	5	,	,	PUNCT
ijpds-3575	42	6	it	it	PRON
ijpds-3575	42	7	becomes	become	VERB
ijpds-3575	42	8	an	an	DET
ijpds-3575	42	9	rna	rna	NOUN
ijpds-3575	42	10	-	-	PUNCT
ijpds-3575	42	11	like	like	ADJ
ijpds-3575	42	12	component	component	NOUN
ijpds-3575	42	13	.	.	PUNCT
ijpds-3575	43	1	in	in	ADP
ijpds-3575	43	2	the	the	DET
ijpds-3575	43	3	first	first	ADJ
ijpds-3575	43	4	step	step	NOUN
ijpds-3575	43	5	,	,	PUNCT
ijpds-3575	43	6	rna	rna	NOUN
ijpds-3575	43	7	polymerase	polymerase	NOUN
ijpds-3575	43	8	incorporates	incorporate	VERB
ijpds-3575	43	9	these	these	DET
ijpds-3575	43	10	components	component	NOUN
ijpds-3575	43	11	into	into	ADP
ijpds-3575	43	12	the	the	DET
ijpds-3575	43	13	rna	rna	NOUN
ijpds-3575	43	14	genome	genome	NOUN
ijpds-3575	43	15	of	of	ADP
ijpds-3575	43	16	the	the	DET
ijpds-3575	43	17	virus	virus	NOUN
ijpds-3575	43	18	.	.	PUNCT
ijpds-3575	44	1	in	in	ADP
ijpds-3575	44	2	the	the	DET
ijpds-3575	44	3	next	next	ADJ
ijpds-3575	44	4	step	step	NOUN
ijpds-3575	44	5	,	,	PUNCT
ijpds-3575	44	6	rna	rna	NOUN
ijpds-3575	44	7	-	-	PUNCT
ijpds-3575	44	8	like	like	ADJ
ijpds-3575	44	9	components	component	NOUN
ijpds-3575	44	10	are	be	AUX
ijpds-3575	44	11	paired	pair	VERB
ijpds-3575	44	12	with	with	ADP
ijpds-3575	44	13	viral	viral	ADJ
ijpds-3575	44	14	genetic	genetic	ADJ
ijpds-3575	44	15	material	material	NOUN
ijpds-3575	44	16	components	component	NOUN
ijpds-3575	44	17	.	.	PUNCT
ijpds-3575	45	1	viral	viral	ADJ
ijpds-3575	45	2	rna	rna	NOUN
ijpds-3575	45	3	contains	contain	VERB
ijpds-3575	45	4	several	several	ADJ
ijpds-3575	45	5	mutations	mutation	NOUN
ijpds-3575	45	6	when	when	SCONJ
ijpds-3575	45	7	it	it	PRON
ijpds-3575	45	8	multiplies	multiply	VERB
ijpds-3575	45	9	to	to	PART
ijpds-3575	45	10	produce	produce	VERB
ijpds-3575	45	11	new	new	ADJ
ijpds-3575	45	12	viruses	virus	NOUN
ijpds-3575	45	13	,	,	PUNCT
ijpds-3575	45	14	preventing	prevent	VERB
ijpds-3575	45	15	the	the	DET
ijpds-3575	45	16	reproduction	reproduction	NOUN
ijpds-3575	45	17	of	of	ADP
ijpds-3575	45	18	the	the	DET
ijpds-3575	45	19	pathogen	pathogen	NOUN
ijpds-3575	45	20	.	.	PUNCT
ijpds-3575	46	1	this	this	DET
ijpds-3575	46	2	viral	viral	ADJ
ijpds-3575	46	3	drug	drug	NOUN
ijpds-3575	46	4	causes	cause	VERB
ijpds-3575	46	5	mutations	mutation	NOUN
ijpds-3575	46	6	in	in	ADP
ijpds-3575	46	7	other	other	ADJ
ijpds-3575	46	8	rna	rna	NOUN
ijpds-3575	46	9	viruses	virus	NOUN
ijpds-3575	46	10	and	and	CCONJ
ijpds-3575	46	11	prevents	prevent	VERB
ijpds-3575	46	12	them	they	PRON
ijpds-3575	46	13	from	from	ADP
ijpds-3575	46	14	expanding	expand	VERB
ijpds-3575	46	15	.	.	PUNCT
ijpds-3575	47	1	molnupiravir	molnupiravir	PROPN
ijpds-3575	47	2	,	,	PUNCT
ijpds-3575	47	3	a	a	DET
ijpds-3575	47	4	promising	promising	ADJ
ijpds-3575	47	5	drug	drug	NOUN
ijpds-3575	47	6	,	,	PUNCT
ijpds-3575	47	7	is	be	AUX
ijpds-3575	47	8	in	in	ADP
ijpds-3575	47	9	the	the	DET
ijpds-3575	47	10	third	third	ADJ
ijpds-3575	47	11	phase	phase	NOUN
ijpds-3575	47	12	of	of	ADP
ijpds-3575	47	13	studies	study	NOUN
ijpds-3575	47	14	.	.	PUNCT
ijpds-3575	48	1	when	when	SCONJ
ijpds-3575	48	2	molnupiravir	molnupiravir	PROPN
ijpds-3575	48	3	enters	enter	VERB
ijpds-3575	48	4	the	the	DET
ijpds-3575	48	5	cell	cell	NOUN
ijpds-3575	48	6	,	,	PUNCT
ijpds-3575	48	7	the	the	DET
ijpds-3575	48	8	active	active	ADJ
ijpds-3575	48	9	molnupiravir	molnupiravir	PROPN
ijpds-3575	48	10	forms	form	NOUN
ijpds-3575	48	11	nhydroxycytidine	nhydroxycytidine	VERB
ijpds-3575	48	12	hydrate	hydrate	ADJ
ijpds-3575	48	13	(	(	PUNCT
ijpds-3575	48	14	nhc	nhc	NOUN
ijpds-3575	48	15	triphosphate	triphosphate	NOUN
ijpds-3575	48	16	(	(	PUNCT
ijpds-3575	48	17	mtp	mtp	PROPN
ijpds-3575	48	18	)	)	PUNCT
ijpds-3575	48	19	,	,	PUNCT
ijpds-3575	48	20	which	which	PRON
ijpds-3575	48	21	can	can	AUX
ijpds-3575	48	22	be	be	AUX
ijpds-3575	48	23	replaced	replace	VERB
ijpds-3575	48	24	by	by	ADP
ijpds-3575	48	25	ctp	ctp	PROPN
ijpds-3575	48	26	or	or	CCONJ
ijpds-3575	48	27	utp	utp	VERB
ijpds-3575	48	28	by	by	ADP
ijpds-3575	48	29	rdrp	rdrp	NOUN
ijpds-3575	48	30	of	of	ADP
ijpds-3575	48	31	sars	sar	NOUN
ijpds-3575	48	32	-	-	PUNCT
ijpds-3575	48	33	cov-2	cov-2	NOUN
ijpds-3575	48	34	.	.	PUNCT
ijpds-3575	48	35	initially	initially	ADV
ijpds-3575	48	36	,	,	PUNCT
ijpds-3575	48	37	when	when	SCONJ
ijpds-3575	48	38	rdrp	rdrp	NOUN
ijpds-3575	48	39	uses	use	VERB
ijpds-3575	48	40	positive	positive	ADJ
ijpds-3575	48	41	-	-	PUNCT
ijpds-3575	48	42	strand	strand	ADJ
ijpds-3575	48	43	genomic	genomic	NOUN
ijpds-3575	48	44	rna	rna	NOUN
ijpds-3575	48	45	for	for	ADP
ijpds-3575	48	46	the	the	DET
ijpds-3575	48	47	synthesis	synthesis	NOUN
ijpds-3575	48	48	sub	sub	ADJ
ijpds-3575	48	49	-	-	ADJ
ijpds-3575	48	50	genomic	genomic	ADJ
ijpds-3575	48	51	rna	rna	NOUN
ijpds-3575	48	52	and	and	CCONJ
ijpds-3575	48	53	negative	negative	ADJ
ijpds-3575	48	54	-	-	PUNCT
ijpds-3575	48	55	strand	strand	ADJ
ijpds-3575	48	56	genomic	genomic	NOUN
ijpds-3575	48	57	rna	rna	NOUN
ijpds-3575	48	58	as	as	ADP
ijpds-3575	48	59	a	a	DET
ijpds-3575	48	60	template	template	NOUN
ijpds-3575	48	61	,	,	PUNCT
ijpds-3575	48	62	it	it	PRON
ijpds-3575	48	63	regularly	regularly	ADV
ijpds-3575	48	64	substitutes	substitute	VERB
ijpds-3575	48	65	m	m	VERB
ijpds-3575	48	66	for	for	ADP
ijpds-3575	48	67	u	u	NOUN
ijpds-3575	48	68	or	or	CCONJ
ijpds-3575	48	69	c.	c.	NOUN
ijpds-3575	48	70	in	in	ADP
ijpds-3575	48	71	the	the	DET
ijpds-3575	48	72	next	next	ADJ
ijpds-3575	48	73	step	step	NOUN
ijpds-3575	48	74	,	,	PUNCT
ijpds-3575	48	75	+	+	NOUN
ijpds-3575	48	76	grna	grna	NOUN
ijpds-3575	48	77	or	or	CCONJ
ijpds-3575	48	78	+	+	NOUN
ijpds-3575	48	79	sgmrna	sgmrna	NOUN
ijpds-3575	48	80	can	can	AUX
ijpds-3575	48	81	be	be	AUX
ijpds-3575	48	82	used	use	VERB
ijpds-3575	48	83	from	from	ADP
ijpds-3575	48	84	rna	rna	NOUN
ijpds-3575	48	85	including	include	VERB
ijpds-3575	48	86	m	m	PRON
ijpds-3575	48	87	as	as	ADP
ijpds-3575	48	88	a	a	DET
ijpds-3575	48	89	template	template	NOUN
ijpds-3575	48	90	.	.	PUNCT
ijpds-3575	49	1	then	then	ADV
ijpds-3575	49	2	mutations	mutation	NOUN
ijpds-3575	49	3	are	be	AUX
ijpds-3575	49	4	formed	form	VERB
ijpds-3575	49	5	in	in	ADP
ijpds-3575	49	6	positive	positive	ADJ
ijpds-3575	49	7	-	-	PUNCT
ijpds-3575	49	8	stranded	strand	VERB
ijpds-3575	49	9	genomic	genomic	ADJ
ijpds-3575	49	10	rna	rna	NOUN
ijpds-3575	49	11	products	product	NOUN
ijpds-3575	49	12	due	due	ADP
ijpds-3575	49	13	to	to	ADP
ijpds-3575	49	14	the	the	DET
ijpds-3575	49	15	presence	presence	NOUN
ijpds-3575	49	16	of	of	ADP
ijpds-3575	49	17	m	m	PROPN
ijpds-3575	49	18	in	in	ADP
ijpds-3575	49	19	negative	negative	ADJ
ijpds-3575	49	20	strand	strand	NOUN
ijpds-3575	49	21	genomic	genomic	NOUN
ijpds-3575	49	22	rna	rna	NOUN
ijpds-3575	49	23	,	,	PUNCT
ijpds-3575	49	24	and	and	CCONJ
ijpds-3575	49	25	these	these	DET
ijpds-3575	49	26	products	product	NOUN
ijpds-3575	49	27	prevent	prevent	VERB
ijpds-3575	49	28	the	the	DET
ijpds-3575	49	29	formation	formation	NOUN
ijpds-3575	49	30	of	of	ADP
ijpds-3575	49	31	healthy	healthy	ADJ
ijpds-3575	49	32	new	new	ADJ
ijpds-3575	49	33	viruses	virus	NOUN
ijpds-3575	49	34	.	.	PUNCT
ijpds-3575	50	1	at	at	ADP
ijpds-3575	50	2	the	the	DET
ijpds-3575	50	3	end	end	NOUN
ijpds-3575	50	4	of	of	ADP
ijpds-3575	50	5	this	this	DET
ijpds-3575	50	6	two	two	NUM
ijpds-3575	50	7	-	-	PUNCT
ijpds-3575	50	8	step	step	NOUN
ijpds-3575	50	9	mechanism	mechanism	NOUN
ijpds-3575	50	10	,	,	PUNCT
ijpds-3575	50	11	the	the	DET
ijpds-3575	50	12	mechanism	mechanism	NOUN
ijpds-3575	50	13	of	of	ADP
ijpds-3575	50	14	molnupiravir	molnupiravir	PROPN
ijpds-3575	50	15	and	and	CCONJ
ijpds-3575	50	16	its	its	PRON
ijpds-3575	50	17	activated	activated	ADJ
ijpds-3575	50	18	type	type	NOUN
ijpds-3575	50	19	were	be	AUX
ijpds-3575	50	20	shownto	shownto	NOUN
ijpds-3575	50	21	result	result	NOUN
ijpds-3575	50	22	in	in	ADP
ijpds-3575	50	23	rna	rna	NOUN
ijpds-3575	50	24	mutations	mutation	NOUN
ijpds-3575	50	25	through	through	ADP
ijpds-3575	50	26	polymerases	polymerase	NOUN
ijpds-3575	50	27	of	of	ADP
ijpds-3575	50	28	other	other	ADJ
ijpds-3575	50	29	viruses	virus	NOUN
ijpds-3575	50	30	.	.	PUNCT
ijpds-3575	51	1	according	accord	VERB
ijpds-3575	51	2	to	to	ADP
ijpds-3575	51	3	previous	previous	ADJ
ijpds-3575	51	4	studies	study	NOUN
ijpds-3575	51	5	,	,	PUNCT
ijpds-3575	51	6	molnupiravir	molnupiravir	PROPN
ijpds-3575	51	7	-	-	PUNCT
ijpds-3575	51	8	induced	induce	VERB
ijpds-3575	51	9	lethal	lethal	ADJ
ijpds-3575	51	10	mutagenesis	mutagenesis	NOUN
ijpds-3575	51	11	was	be	AUX
ijpds-3575	51	12	determined	determine	VERB
ijpds-3575	51	13	by	by	ADP
ijpds-3575	51	14	a	a	DET
ijpds-3575	51	15	relatively	relatively	ADV
ijpds-3575	51	16	high	high	ADJ
ijpds-3575	51	17	selectivity	selectivity	NOUN
ijpds-3575	51	18	of	of	ADP
ijpds-3575	51	19	mtp	mtp	PROPN
ijpds-3575	51	20	for	for	ADP
ijpds-3575	51	21	incorporation	incorporation	NOUN
ijpds-3575	51	22	as	as	ADP
ijpds-3575	51	23	a	a	DET
ijpds-3575	51	24	ctp	ctp	NOUN
ijpds-3575	51	25	analogue	analogue	NOUN
ijpds-3575	51	26	and	and	CCONJ
ijpds-3575	51	27	the	the	DET
ijpds-3575	51	28	indiscriminate	indiscriminate	ADJ
ijpds-3575	51	29	incorporation	incorporation	NOUN
ijpds-3575	51	30	of	of	ADP
ijpds-3575	51	31	either	either	CCONJ
ijpds-3575	51	32	atp	atp	PROPN
ijpds-3575	51	33	or	or	CCONJ
ijpds-3575	51	34	gtp	gtp	NOUN
ijpds-3575	51	35	when	when	SCONJ
ijpds-3575	51	36	mnp	mnp	PROPN
ijpds-3575	51	37	is	be	AUX
ijpds-3575	51	38	centralized	centralize	VERB
ijpds-3575	51	39	in	in	ADP
ijpds-3575	51	40	the	the	DET
ijpds-3575	51	41	template	template	NOUN
ijpds-3575	51	42	strand	strand	NOUN
ijpds-3575	52	1	[	[	X
ijpds-3575	52	2	19	19	NUM
ijpds-3575	52	3	]	]	PUNCT
ijpds-3575	52	4	.	.	PUNCT
ijpds-3575	53	1	favipiravir	favipiravir	PROPN
ijpds-3575	53	2	favipiravir	favipiravir	PROPN
ijpds-3575	53	3	(	(	PUNCT
ijpds-3575	53	4	6	6	NUM
ijpds-3575	53	5	-	-	PUNCT
ijpds-3575	53	6	fluoro-3	fluoro-3	VERB
ijpds-3575	53	7	-	-	PUNCT
ijpds-3575	53	8	hydroxypyrazine-2	hydroxypyrazine-2	ADV
ijpds-3575	53	9	-	-	PUNCT
ijpds-3575	53	10	carboxamine	carboxamine	NOUN
ijpds-3575	53	11	)	)	PUNCT
ijpds-3575	53	12	which	which	PRON
ijpds-3575	53	13	is	be	AUX
ijpds-3575	53	14	a	a	DET
ijpds-3575	53	15	prodrug	prodrug	NOUN
ijpds-3575	53	16	,	,	PUNCT
ijpds-3575	53	17	is	be	AUX
ijpds-3575	53	18	an	an	DET
ijpds-3575	53	19	anti	anti	ADJ
ijpds-3575	53	20	-	-	ADJ
ijpds-3575	53	21	influenza	influenza	ADJ
ijpds-3575	53	22	drug	drug	NOUN
ijpds-3575	53	23	that	that	PRON
ijpds-3575	53	24	has	have	AUX
ijpds-3575	53	25	shown	show	VERB
ijpds-3575	53	26	broad	broad	ADJ
ijpds-3575	53	27	-	-	PUNCT
ijpds-3575	53	28	spectrum	spectrum	NOUN
ijpds-3575	53	29	antiviral	antiviral	ADJ
ijpds-3575	53	30	activity	activity	NOUN
ijpds-3575	53	31	against	against	ADP
ijpds-3575	53	32	a	a	DET
ijpds-3575	53	33	variety	variety	NOUN
ijpds-3575	53	34	of	of	ADP
ijpds-3575	53	35	other	other	ADJ
ijpds-3575	53	36	rna	rna	NOUN
ijpds-3575	53	37	viruses	virus	NOUN
ijpds-3575	53	38	.	.	PUNCT
ijpds-3575	54	1	this	this	DET
ijpds-3575	54	2	antiviral	antiviral	ADJ
ijpds-3575	54	3	drug	drug	NOUN
ijpds-3575	54	4	metabolized	metabolize	VERB
ijpds-3575	54	5	intracellularly	intracellularly	ADV
ijpds-3575	54	6	into	into	ADP
ijpds-3575	54	7	its	its	PRON
ijpds-3575	54	8	active	active	ADJ
ijpds-3575	54	9	ribonucleoside	ribonucleoside	NOUN
ijpds-3575	54	10	5′-triphosphate	5′-triphosphate	PROPN
ijpds-3575	54	11	form	form	NOUN
ijpds-3575	54	12	that	that	PRON
ijpds-3575	54	13	acts	act	VERB
ijpds-3575	54	14	as	as	ADP
ijpds-3575	54	15	a	a	DET
ijpds-3575	54	16	nucleotide	nucleotide	ADJ
ijpds-3575	54	17	analogue	analogue	NOUN
ijpds-3575	54	18	to	to	PART
ijpds-3575	54	19	selectively	selectively	ADV
ijpds-3575	54	20	inhibit	inhibit	VERB
ijpds-3575	54	21	rdrp	rdrp	NOUN
ijpds-3575	54	22	and	and	CCONJ
ijpds-3575	54	23	induce	induce	VERB
ijpds-3575	54	24	lethal	lethal	ADJ
ijpds-3575	54	25	mutagenesis	mutagenesis	NOUN
ijpds-3575	54	26	.	.	PUNCT
ijpds-3575	55	1	recently	recently	ADV
ijpds-3575	55	2	,	,	PUNCT
ijpds-3575	55	3	several	several	ADJ
ijpds-3575	55	4	studies	study	NOUN
ijpds-3575	55	5	reported	report	VERB
ijpds-3575	55	6	in	in	ADP
ijpds-3575	55	7	vitro	vitro	X
ijpds-3575	55	8	inhibitory	inhibitory	ADJ
ijpds-3575	55	9	activity	activity	NOUN
ijpds-3575	55	10	of	of	ADP
ijpds-3575	55	11	favipiravir	favipiravir	NOUN
ijpds-3575	55	12	against	against	ADP
ijpds-3575	55	13	sars	sar	NOUN
ijpds-3575	55	14	-	-	PUNCT
ijpds-3575	55	15	cov-2	cov-2	NOUN
ijpds-3575	55	16	with	with	ADP
ijpds-3575	55	17	50	50	NUM
ijpds-3575	55	18	%	%	NOUN
ijpds-3575	55	19	ec50	ec50	PROPN
ijpds-3575	55	20	.	.	PUNCT
ijpds-3575	56	1	based	base	VERB
ijpds-3575	56	2	on	on	ADP
ijpds-3575	56	3	these	these	DET
ijpds-3575	56	4	results	result	NOUN
ijpds-3575	56	5	,	,	PUNCT
ijpds-3575	56	6	more	more	ADJ
ijpds-3575	56	7	than	than	ADP
ijpds-3575	56	8	20	20	NUM
ijpds-3575	56	9	clinical	clinical	ADJ
ijpds-3575	56	10	trials	trial	NOUN
ijpds-3575	56	11	on	on	ADP
ijpds-3575	56	12	the	the	DET
ijpds-3575	56	13	management	management	NOUN
ijpds-3575	56	14	of	of	ADP
ijpds-3575	56	15	covid-19	covid-19	PROPN
ijpds-3575	56	16	by	by	ADP
ijpds-3575	56	17	favipiravir	favipiravir	NOUN
ijpds-3575	56	18	are	be	AUX
ijpds-3575	56	19	ongoing	ongoing	ADJ
ijpds-3575	56	20	.	.	PUNCT
ijpds-3575	57	1	table	table	NOUN
ijpds-3575	57	2	1	1	NUM
ijpds-3575	57	3	:	:	PUNCT
ijpds-3575	57	4	variant	variant	NOUN
ijpds-3575	57	5	of	of	ADP
ijpds-3575	57	6	sars	sar	NOUN
ijpds-3575	57	7	-	-	PUNCT
ijpds-3575	57	8	cov-2	cov-2	NOUN
ijpds-3575	57	9	variant	variant	ADJ
ijpds-3575	57	10	strain	strain	NOUN
ijpds-3575	57	11	description	description	NOUN
ijpds-3575	57	12	references	reference	NOUN
ijpds-3575	57	13	voc	voc	PROPN
ijpds-3575	57	14	alpha	alpha	PROPN
ijpds-3575	57	15	detected	detect	VERB
ijpds-3575	57	16	in	in	ADP
ijpds-3575	57	17	oct	oct	PROPN
ijpds-3575	57	18	2020	2020	NUM
ijpds-3575	57	19	and	and	CCONJ
ijpds-3575	57	20	correlated	correlate	VERB
ijpds-3575	57	21	with	with	ADP
ijpds-3575	57	22	a	a	DET
ijpds-3575	57	23	significant	significant	ADJ
ijpds-3575	57	24	increase	increase	NOUN
ijpds-3575	57	25	in	in	ADP
ijpds-3575	57	26	the	the	DET
ijpds-3575	57	27	rate	rate	NOUN
ijpds-3575	57	28	of	of	ADP
ijpds-3575	57	29	covid19	covid19	NOUN
ijpds-3575	57	30	infection	infection	NOUN
ijpds-3575	57	31	.	.	PUNCT
ijpds-3575	58	1	[	[	X
ijpds-3575	58	2	11	11	NUM
ijpds-3575	58	3	]	]	X
ijpds-3575	58	4	voc	voc	NOUN
ijpds-3575	58	5	beta	beta	PROPN
ijpds-3575	58	6	detected	detect	VERB
ijpds-3575	58	7	in	in	ADP
ijpds-3575	58	8	18	18	NUM
ijpds-3575	58	9	december	december	NOUN
ijpds-3575	58	10	2020	2020	NUM
ijpds-3575	58	11	in	in	ADP
ijpds-3575	58	12	south	south	PROPN
ijpds-3575	58	13	africa	africa	PROPN
ijpds-3575	58	14	.	.	PUNCT
ijpds-3575	59	1	[	[	X
ijpds-3575	59	2	12	12	NUM
ijpds-3575	59	3	]	]	X
ijpds-3575	59	4	voc	voc	NOUN
ijpds-3575	59	5	gamma	gamma	PROPN
ijpds-3575	59	6	detected	detect	VERB
ijpds-3575	59	7	in	in	ADP
ijpds-3575	59	8	tokyo	tokyo	PROPN
ijpds-3575	59	9	on	on	ADP
ijpds-3575	59	10	6	6	NUM
ijpds-3575	59	11	january	january	NOUN
ijpds-3575	59	12	2021	2021	NUM
ijpds-3575	59	13	by	by	ADP
ijpds-3575	59	14	national	national	ADJ
ijpds-3575	59	15	institutes	institute	NOUN
ijpds-3575	59	16	of	of	ADP
ijpds-3575	59	17	infectious	infectious	ADJ
ijpds-3575	59	18	diseases	disease	NOUN
ijpds-3575	59	19	[	[	X
ijpds-3575	59	20	13	13	NUM
ijpds-3575	59	21	]	]	X
ijpds-3575	59	22	voc	voc	NOUN
ijpds-3575	59	23	delta	delta	PROPN
ijpds-3575	59	24	detected	detect	VERB
ijpds-3575	59	25	in	in	ADP
ijpds-3575	59	26	6	6	NUM
ijpds-3575	59	27	may	may	NOUN
ijpds-3575	59	28	2021	2021	NUM
ijpds-3575	59	29	and	and	CCONJ
ijpds-3575	59	30	it	it	PRON
ijpds-3575	59	31	is	be	AUX
ijpds-3575	59	32	globally	globally	ADV
ijpds-3575	59	33	dominant	dominant	ADJ
ijpds-3575	59	34	variant	variant	NOUN
ijpds-3575	59	35	[	[	X
ijpds-3575	59	36	14	14	NUM
ijpds-3575	59	37	]	]	X
ijpds-3575	59	38	voc	voc	PROPN
ijpds-3575	59	39	omicron	omicron	PROPN
ijpds-3575	59	40	detected	detect	VERB
ijpds-3575	59	41	in	in	ADP
ijpds-3575	59	42	26	26	NUM
ijpds-3575	59	43	november	november	PROPN
ijpds-3575	59	44	2021	2021	NUM
ijpds-3575	59	45	in	in	ADP
ijpds-3575	59	46	south	south	PROPN
ijpds-3575	59	47	africa	africa	PROPN
ijpds-3575	59	48	.	.	PUNCT
ijpds-3575	60	1	[	[	X
ijpds-3575	60	2	15,16	15,16	NUM
ijpds-3575	60	3	]	]	X
ijpds-3575	60	4	voi	voi	NOUN
ijpds-3575	60	5	lambda	lambda	NOUN
ijpds-3575	60	6	detected	detect	VERB
ijpds-3575	60	7	in	in	ADP
ijpds-3575	60	8	peru	peru	PROPN
ijpds-3575	60	9	in	in	ADP
ijpds-3575	60	10	august	august	PROPN
ijpds-3575	60	11	2020	2020	NUM
ijpds-3575	60	12	[	[	X
ijpds-3575	60	13	17	17	NUM
ijpds-3575	60	14	]	]	X
ijpds-3575	60	15	voi	voi	PROPN
ijpds-3575	60	16	mu	mu	NOUN
ijpds-3575	60	17	detected	detect	VERB
ijpds-3575	60	18	in	in	ADP
ijpds-3575	60	19	colombia	colombia	PROPN
ijpds-3575	60	20	in	in	ADP
ijpds-3575	60	21	january	january	PROPN
ijpds-3575	60	22	2021	2021	NUM
ijpds-3575	60	23	.	.	PUNCT
ijpds-3575	61	1	[	[	X
ijpds-3575	61	2	18	18	NUM
ijpds-3575	61	3	]	]	X
ijpds-3575	61	4	singh	singh	PROPN
ijpds-3575	61	5	et	et	PROPN
ijpds-3575	61	6	al	al	PROPN
ijpds-3575	61	7	.	.	PROPN
ijpds-3575	61	8	molnupiravir	molnupiravir	PROPN
ijpds-3575	61	9	and	and	CCONJ
ijpds-3575	61	10	favipiravir	favipiravir	PROPN
ijpds-3575	61	11	in	in	ADP
ijpds-3575	61	12	sars	sars	PROPN
ijpds-3575	61	13	-	-	PUNCT
ijpds-3575	61	14	cov-2	cov-2	PART
ijpds-3575	61	15	vol	vol	NOUN
ijpds-3575	61	16	1	1	NUM
ijpds-3575	61	17	|	|	ADV
ijpds-3575	61	18	issue	issue	VERB
ijpds-3575	61	19	3	3	NUM
ijpds-3575	61	20	|	|	ADV
ijpds-3575	61	21	oct	oct	PROPN
ijpds-3575	61	22	dec	dec	PROPN
ijpds-3575	61	23	2022	2022	NUM
ijpds-3575	61	24	indian	indian	PROPN
ijpds-3575	61	25	j	j	PROPN
ijpds-3575	61	26	pharm	pharm	PROPN
ijpds-3575	61	27	drug	drug	PROPN
ijpds-3575	61	28	studies	study	NOUN
ijpds-3575	61	29	|	|	ADV
ijpds-3575	61	30	75	75	NUM
ijpds-3575	61	31	figure	figure	NOUN
ijpds-3575	61	32	4(b	4(b	NUM
ijpds-3575	61	33	):	):	PUNCT
ijpds-3575	61	34	mechanism	mechanism	NOUN
ijpds-3575	61	35	of	of	ADP
ijpds-3575	61	36	action	action	NOUN
ijpds-3575	61	37	of	of	ADP
ijpds-3575	61	38	favipiravir	favipiravir	PROPN
ijpds-3575	61	39	(	(	PUNCT
ijpds-3575	61	40	favipiravir	favipiravir	PROPN
ijpds-3575	61	41	-	-	PUNCT
ijpds-3575	61	42	rmp	rmp	PROPN
ijpds-3575	61	43	phosphorylates	phosphorylate	NOUN
ijpds-3575	61	44	and	and	CCONJ
ijpds-3575	61	45	produce	produce	VERB
ijpds-3575	61	46	favipiravir	favipiravir	NOUN
ijpds-3575	61	47	-	-	PUNCT
ijpds-3575	61	48	rtp	rtp	PROPN
ijpds-3575	61	49	in	in	ADP
ijpds-3575	61	50	active	active	ADJ
ijpds-3575	61	51	form	form	NOUN
ijpds-3575	61	52	)	)	PUNCT
ijpds-3575	61	53	table	table	NOUN
ijpds-3575	61	54	2	2	NUM
ijpds-3575	61	55	miscellaneous	miscellaneous	ADJ
ijpds-3575	61	56	anti	anti	ADJ
ijpds-3575	61	57	-	-	ADJ
ijpds-3575	61	58	viral	viral	ADJ
ijpds-3575	61	59	drugs	drug	NOUN
ijpds-3575	61	60	used	use	VERB
ijpds-3575	61	61	in	in	ADP
ijpds-3575	61	62	the	the	DET
ijpds-3575	61	63	treatment	treatment	NOUN
ijpds-3575	61	64	of	of	ADP
ijpds-3575	61	65	covid-19	covid-19	PROPN
ijpds-3575	61	66	and	and	CCONJ
ijpds-3575	61	67	their	their	PRON
ijpds-3575	61	68	respective	respective	ADJ
ijpds-3575	61	69	deadly	deadly	ADJ
ijpds-3575	61	70	strains	strain	NOUN
ijpds-3575	61	71	drug	drug	NOUN
ijpds-3575	61	72	structure	structure	NOUN
ijpds-3575	61	73	mechanism	mechanism	NOUN
ijpds-3575	61	74	of	of	ADP
ijpds-3575	61	75	action	action	NOUN
ijpds-3575	61	76	remdesivir	remdesivir	VERB
ijpds-3575	61	77	the	the	DET
ijpds-3575	61	78	active	active	ADJ
ijpds-3575	61	79	metabolite	metabolite	NOUN
ijpds-3575	61	80	of	of	ADP
ijpds-3575	61	81	this	this	DET
ijpds-3575	61	82	drug	drug	NOUN
ijpds-3575	61	83	interferes	interfere	VERB
ijpds-3575	61	84	with	with	ADP
ijpds-3575	61	85	the	the	DET
ijpds-3575	61	86	action	action	NOUN
ijpds-3575	61	87	of	of	ADP
ijpds-3575	61	88	rdrp	rdrp	NOUN
ijpds-3575	61	89	and	and	CCONJ
ijpds-3575	61	90	evades	evade	VERB
ijpds-3575	61	91	profeeding	profeede	VERB
ijpds-3575	61	92	by	by	ADP
ijpds-3575	61	93	viral	viral	ADJ
ijpds-3575	61	94	exoribonucleaases	exoribonucleaase	NOUN
ijpds-3575	61	95	causing	cause	VERB
ijpds-3575	61	96	a	a	DET
ijpds-3575	61	97	reduction	reduction	NOUN
ijpds-3575	61	98	in	in	ADP
ijpds-3575	61	99	the	the	DET
ijpds-3575	61	100	synthesis	synthesis	NOUN
ijpds-3575	61	101	of	of	ADP
ijpds-3575	61	102	rna	rna	NOUN
ijpds-3575	61	103	alisopirivir/	alisopirivir/	NUM
ijpds-3575	61	104	debio	debio	NOUN
ijpds-3575	61	105	025/	025/	NOUN
ijpds-3575	61	106	unil-025	unil-025	NOUN
ijpds-3575	61	107	abolish	abolish	VERB
ijpds-3575	61	108	cyclophilin	cyclophilin	PROPN
ijpds-3575	61	109	a	a	PRON
ijpds-3575	61	110	or	or	CCONJ
ijpds-3575	61	111	rotamase	rotamase	VERB
ijpds-3575	61	112	a	a	DET
ijpds-3575	61	113	figure	figure	NOUN
ijpds-3575	61	114	2	2	NUM
ijpds-3575	61	115	:	:	PUNCT
ijpds-3575	61	116	mechanism	mechanism	NOUN
ijpds-3575	61	117	of	of	ADP
ijpds-3575	61	118	action	action	NOUN
ijpds-3575	61	119	of	of	ADP
ijpds-3575	61	120	molnupiravir	molnupiravir	PROPN
ijpds-3575	61	121	fig	fig	NOUN
ijpds-3575	61	122	3	3	NUM
ijpds-3575	61	123	:	:	PUNCT
ijpds-3575	61	124	chemical	chemical	ADJ
ijpds-3575	61	125	structure	structure	NOUN
ijpds-3575	61	126	of	of	ADP
ijpds-3575	61	127	favipiravir	favipiravir	PROPN
ijpds-3575	61	128	figure	figure	VERB
ijpds-3575	61	129	4	4	NUM
ijpds-3575	61	130	(	(	PUNCT
ijpds-3575	61	131	a	a	PRON
ijpds-3575	61	132	):	):	PUNCT
ijpds-3575	61	133	mechanism	mechanism	NOUN
ijpds-3575	61	134	of	of	ADP
ijpds-3575	61	135	favipiravir	favipiravir	PROPN
ijpds-3575	61	136	singh	singh	PROPN
ijpds-3575	61	137	et	et	PROPN
ijpds-3575	61	138	al	al	PROPN
ijpds-3575	61	139	.	.	PROPN
ijpds-3575	62	1	molnupiravir	molnupiravir	PROPN
ijpds-3575	62	2	and	and	CCONJ
ijpds-3575	62	3	favipiravir	favipiravir	PROPN
ijpds-3575	62	4	in	in	ADP
ijpds-3575	62	5	sars	sars	PROPN
ijpds-3575	62	6	-	-	PUNCT
ijpds-3575	62	7	cov-2	cov-2	PART
ijpds-3575	62	8	vol	vol	NOUN
ijpds-3575	62	9	1	1	NUM
ijpds-3575	62	10	|	|	ADV
ijpds-3575	62	11	issue	issue	VERB
ijpds-3575	62	12	3	3	NUM
ijpds-3575	62	13	|	|	ADV
ijpds-3575	62	14	oct	oct	PROPN
ijpds-3575	62	15	dec	dec	PROPN
ijpds-3575	62	16	2022	2022	NUM
ijpds-3575	62	17	indian	indian	PROPN
ijpds-3575	62	18	j	j	PROPN
ijpds-3575	62	19	pharm	pharm	PROPN
ijpds-3575	62	20	drug	drug	PROPN
ijpds-3575	62	21	studies	study	NOUN
ijpds-3575	62	22	|	|	ADV
ijpds-3575	62	23	76	76	NUM
ijpds-3575	62	24	umifenovir	umifenovir	NOUN
ijpds-3575	62	25	it	it	PRON
ijpds-3575	62	26	suppress	suppress	VERB
ijpds-3575	62	27	the	the	DET
ijpds-3575	62	28	membrane	membrane	NOUN
ijpds-3575	62	29	fusion	fusion	NOUN
ijpds-3575	62	30	of	of	ADP
ijpds-3575	62	31	influenza	influenza	NOUN
ijpds-3575	62	32	virus	virus	NOUN
ijpds-3575	62	33	and	and	CCONJ
ijpds-3575	62	34	orifice	orifice	NOUN
ijpds-3575	62	35	impinging	impinge	VERB
ijpds-3575	62	36	betwixt	betwixt	VERB
ijpds-3575	62	37	the	the	DET
ijpds-3575	62	38	virus	virus	NOUN
ijpds-3575	62	39	and	and	CCONJ
ijpds-3575	62	40	target	target	VERB
ijpds-3575	62	41	host	host	NOUN
ijpds-3575	62	42	cell	cell	NOUN
ijpds-3575	62	43	.	.	PUNCT
ijpds-3575	63	1	galidesivir/	galidesivir/	NOUN
ijpds-3575	63	2	bcx4430/	bcx4430/	PROPN
ijpds-3575	63	3	immucillina	immucillina	NOUN
ijpds-3575	63	4	this	this	PRON
ijpds-3575	63	5	is	be	AUX
ijpds-3575	63	6	under	under	ADP
ijpds-3575	63	7	phase	phase	NOUN
ijpds-3575	63	8	1	1	NUM
ijpds-3575	63	9	human	human	ADJ
ijpds-3575	63	10	trail	trail	NOUN
ijpds-3575	63	11	in	in	ADP
ijpds-3575	63	12	brazil	brazil	PROPN
ijpds-3575	63	13	for	for	ADP
ijpds-3575	63	14	sars	sar	NOUN
ijpds-3575	63	15	-	-	PUNCT
ijpds-3575	63	16	cov-2	cov-2	PART
ijpds-3575	63	17	and	and	CCONJ
ijpds-3575	63	18	possess	possess	VERB
ijpds-3575	63	19	broad	broad	ADJ
ijpds-3575	63	20	spectrum	spectrum	NOUN
ijpds-3575	63	21	antiviral	antiviral	ADJ
ijpds-3575	63	22	potency	potency	NOUN
ijpds-3575	63	23	against	against	ADP
ijpds-3575	63	24	virus	virus	NOUN
ijpds-3575	63	25	belongs	belong	VERB
ijpds-3575	63	26	to	to	ADP
ijpds-3575	63	27	rna	rna	NOUN
ijpds-3575	63	28	families	family	NOUN
ijpds-3575	63	29	involving	involve	VERB
ijpds-3575	63	30	bunyaviruses	bunyavirus	NOUN
ijpds-3575	63	31	,	,	PUNCT
ijpds-3575	63	32	marburg	marburg	PROPN
ijpds-3575	63	33	virus	virus	NOUN
ijpds-3575	63	34	disease	disease	PROPN
ijpds-3575	63	35	,	,	PUNCT
ijpds-3575	63	36	zika	zika	X
ijpds-3575	63	37	virus	virus	NOUN
ijpds-3575	63	38	,	,	PUNCT
ijpds-3575	63	39	ebola	ebola	PROPN
ijpds-3575	63	40	virus	virus	PROPN
ijpds-3575	63	41	,	,	PUNCT
ijpds-3575	63	42	arenaviruses	arenavirus	NOUN
ijpds-3575	63	43	,	,	PUNCT
ijpds-3575	63	44	flaviviruses	flavivirus	NOUN
ijpds-3575	63	45	,	,	PUNCT
ijpds-3575	63	46	phleboviruses	phleboviruse	NOUN
ijpds-3575	63	47	,	,	PUNCT
ijpds-3575	63	48	paramyxoviruses	paramyxoviruse	VERB
ijpds-3575	63	49	nelfinavir	nelfinavir	PRON
ijpds-3575	63	50	this	this	DET
ijpds-3575	63	51	medication	medication	NOUN
ijpds-3575	63	52	is	be	AUX
ijpds-3575	63	53	a	a	DET
ijpds-3575	63	54	competitive	competitive	ADJ
ijpds-3575	63	55	inhibitor	inhibitor	NOUN
ijpds-3575	63	56	and	and	CCONJ
ijpds-3575	63	57	protease	protease	NOUN
ijpds-3575	63	58	inhibitor	inhibitor	NOUN
ijpds-3575	63	59	with	with	ADP
ijpds-3575	63	60	activity	activity	NOUN
ijpds-3575	63	61	against	against	ADP
ijpds-3575	63	62	hiv-1	hiv-1	NOUN
ijpds-3575	63	63	.	.	PUNCT
ijpds-3575	63	64	lopinavir	lopinavir	NOUN
ijpds-3575	63	65	this	this	DET
ijpds-3575	63	66	drug	drug	NOUN
ijpds-3575	63	67	also	also	ADV
ijpds-3575	63	68	inhibit	inhibit	VERB
ijpds-3575	63	69	the	the	DET
ijpds-3575	63	70	hiv	hiv	PROPN
ijpds-3575	63	71	protease	protease	NOUN
ijpds-3575	63	72	enzyme	enzyme	NOUN
ijpds-3575	63	73	by	by	ADP
ijpds-3575	63	74	producing	produce	VERB
ijpds-3575	63	75	an	an	DET
ijpds-3575	63	76	enzyme	enzyme	NOUN
ijpds-3575	63	77	inhibitor	inhibitor	NOUN
ijpds-3575	63	78	complex	complex	NOUN
ijpds-3575	63	79	,	,	PUNCT
ijpds-3575	63	80	thus	thus	ADV
ijpds-3575	63	81	preventing	prevent	VERB
ijpds-3575	63	82	the	the	DET
ijpds-3575	63	83	segmentation	segmentation	NOUN
ijpds-3575	63	84	of	of	ADP
ijpds-3575	63	85	the	the	DET
ijpds-3575	63	86	gag	gag	NOUN
ijpds-3575	63	87	-	-	PUNCT
ijpds-3575	63	88	pol	pol	NOUN
ijpds-3575	63	89	polyproteins	polyprotein	NOUN
ijpds-3575	63	90	ritonavir	ritonavir	PROPN
ijpds-3575	63	91	generally	generally	ADV
ijpds-3575	63	92	,	,	PUNCT
ijpds-3575	63	93	this	this	DET
ijpds-3575	63	94	medication	medication	NOUN
ijpds-3575	63	95	abolishes	abolish	VERB
ijpds-3575	63	96	the	the	DET
ijpds-3575	63	97	hiv	hiv	PROPN
ijpds-3575	63	98	viral	viral	ADJ
ijpds-3575	63	99	proteinase	proteinase	NOUN
ijpds-3575	63	100	enzyme	enzyme	NOUN
ijpds-3575	63	101	that	that	PRON
ijpds-3575	63	102	normally	normally	ADV
ijpds-3575	63	103	breaks	break	VERB
ijpds-3575	63	104	the	the	DET
ijpds-3575	63	105	structural	structural	ADJ
ijpds-3575	63	106	and	and	CCONJ
ijpds-3575	63	107	replicative	replicative	ADJ
ijpds-3575	63	108	proteins	protein	NOUN
ijpds-3575	63	109	that	that	PRON
ijpds-3575	63	110	arises	arise	VERB
ijpds-3575	63	111	from	from	ADP
ijpds-3575	63	112	major	major	ADJ
ijpds-3575	63	113	hiv	hiv	PROPN
ijpds-3575	63	114	genes	gene	NOUN
ijpds-3575	63	115	.	.	PUNCT
ijpds-3575	64	1	table	table	NOUN
ijpds-3575	64	2	3	3	NUM
ijpds-3575	64	3	:	:	PUNCT
ijpds-3575	64	4	clinical	clinical	ADJ
ijpds-3575	64	5	trial	trial	NOUN
ijpds-3575	64	6	of	of	ADP
ijpds-3575	64	7	several	several	ADJ
ijpds-3575	64	8	medications	medication	NOUN
ijpds-3575	64	9	that	that	PRON
ijpds-3575	64	10	are	be	AUX
ijpds-3575	64	11	utilized	utilize	VERB
ijpds-3575	64	12	in	in	ADP
ijpds-3575	64	13	the	the	DET
ijpds-3575	64	14	therapeutics	therapeutic	NOUN
ijpds-3575	64	15	of	of	ADP
ijpds-3575	64	16	sars	sar	NOUN
ijpds-3575	64	17	-	-	PUNCT
ijpds-3575	64	18	cov-2	cov-2	NOUN
ijpds-3575	64	19	identifier	identifier	NOUN
ijpds-3575	64	20	number	number	NOUN
ijpds-3575	64	21	drug	drug	NOUN
ijpds-3575	64	22	sponsor	sponsor	NOUN
ijpds-3575	64	23	sponsor	sponsor	NOUN
ijpds-3575	64	24	status	status	NOUN
ijpds-3575	64	25	enrollment	enrollment	PROPN
ijpds-3575	64	26	nct04323527	nct04323527	PROPN
ijpds-3575	64	27	chloroquine	chloroquine	PROPN
ijpds-3575	64	28	diphosphate	diphosphate	PROPN
ijpds-3575	64	29	fundação	fundação	PROPN
ijpds-3575	64	30	de	de	PROPN
ijpds-3575	64	31	medicina	medicina	PROPN
ijpds-3575	64	32	tropical	tropical	PROPN
ijpds-3575	64	33	dr	dr	PROPN
ijpds-3575	64	34	.	.	PROPN
ijpds-3575	64	35	heitor	heitor	PROPN
ijpds-3575	64	36	vieira	vieira	PROPN
ijpds-3575	64	37	dourado	dourado	PROPN
ijpds-3575	64	38	completed	complete	VERB
ijpds-3575	64	39	278	278	NUM
ijpds-3575	64	40	nct04343729	nct04343729	NOUN
ijpds-3575	64	41	methylprednisolone	methylprednisolone	PROPN
ijpds-3575	64	42	fundação	fundação	PROPN
ijpds-3575	64	43	de	de	PROPN
ijpds-3575	64	44	medicina	medicina	PROPN
ijpds-3575	64	45	tropical	tropical	PROPN
ijpds-3575	64	46	dr	dr	PROPN
ijpds-3575	64	47	.	.	PROPN
ijpds-3575	64	48	heitor	heitor	PROPN
ijpds-3575	64	49	vieira	vieira	PROPN
ijpds-3575	64	50	dourado	dourado	PROPN
ijpds-3575	64	51	completed	complete	VERB
ijpds-3575	64	52	416	416	NUM
ijpds-3575	64	53	nct04853199	nct04853199	NOUN
ijpds-3575	64	54	quercetin	quercetin	NOUN
ijpds-3575	64	55	hôpital	hôpital	PROPN
ijpds-3575	64	56	universitaire	universitaire	PROPN
ijpds-3575	64	57	sahloul	sahloul	ADP
ijpds-3575	64	58	recruiting	recruit	VERB
ijpds-3575	64	59	200	200	NUM
ijpds-3575	64	60	nct04334148	nct04334148	NOUN
ijpds-3575	64	61	hydroxychloroquine	hydroxychloroquine	PROPN
ijpds-3575	64	62	adrian	adrian	PROPN
ijpds-3575	64	63	hernandez	hernandez	PROPN
ijpds-3575	64	64	completed	complete	VERB
ijpds-3575	64	65	1360	1360	NUM
ijpds-3575	64	66	nct04510493	nct04510493	NOUN
ijpds-3575	64	67	canakinumab	canakinumab	PROPN
ijpds-3575	64	68	university	university	PROPN
ijpds-3575	64	69	hospital	hospital	NOUN
ijpds-3575	64	70	,	,	PUNCT
ijpds-3575	64	71	basel	basel	PROPN
ijpds-3575	64	72	,	,	PUNCT
ijpds-3575	64	73	switzerland	switzerland	PROPN
ijpds-3575	64	74	completed	complete	VERB
ijpds-3575	64	75	116	116	NUM
ijpds-3575	64	76	nct04842747	nct04842747	ADJ
ijpds-3575	64	77	veru-111	veru-111	PROPN
ijpds-3575	64	78	veru	veru	PROPN
ijpds-3575	64	79	inc	inc	PROPN
ijpds-3575	64	80	.	.	PROPN
ijpds-3575	64	81	recruiting	recruit	VERB
ijpds-3575	64	82	300	300	NUM
ijpds-3575	64	83	nct04602000	nct04602000	NOUN
ijpds-3575	64	84	ct	ct	PROPN
ijpds-3575	64	85	-	-	PUNCT
ijpds-3575	64	86	p59	p59	NOUN
ijpds-3575	64	87	celltrion	celltrion	NOUN
ijpds-3575	64	88	completed	complete	VERB
ijpds-3575	64	89	1642	1642	NUM
ijpds-3575	64	90	nct04978025	nct04978025	NOUN
ijpds-3575	64	91	colloidal	colloidal	NOUN
ijpds-3575	64	92	silver	silver	PROPN
ijpds-3575	64	93	hôpital	hôpital	PROPN
ijpds-3575	64	94	universitaire	universitaire	PROPN
ijpds-3575	64	95	sahloul	sahloul	ADP
ijpds-3575	64	96	recruiting	recruit	VERB
ijpds-3575	64	97	50	50	NUM
ijpds-3575	64	98	nct04646044	nct04646044	NOUN
ijpds-3575	64	99	bempegaldesleukin	bempegaldesleukin	PROPN
ijpds-3575	64	100	nektar	nektar	PROPN
ijpds-3575	64	101	therapeutics	therapeutic	NOUN
ijpds-3575	64	102	completed	complete	VERB
ijpds-3575	64	103	30	30	NUM
ijpds-3575	64	104	nct04560231	nct04560231	ADJ
ijpds-3575	64	105	remdesivir	remdesivir	NOUN
ijpds-3575	64	106	lahore	lahore	VERB
ijpds-3575	64	107	general	general	ADJ
ijpds-3575	64	108	hospital	hospital	NOUN
ijpds-3575	64	109	recruiting	recruit	VERB
ijpds-3575	64	110	30	30	NUM
ijpds-3575	65	1	singh	singh	PROPN
ijpds-3575	65	2	et	et	PROPN
ijpds-3575	65	3	al	al	PROPN
ijpds-3575	65	4	.	.	PROPN
ijpds-3575	65	5	molnupiravir	molnupiravir	PROPN
ijpds-3575	65	6	and	and	CCONJ
ijpds-3575	65	7	favipiravir	favipiravir	PROPN
ijpds-3575	65	8	in	in	ADP
ijpds-3575	65	9	sars	sars	PROPN
ijpds-3575	65	10	-	-	PUNCT
ijpds-3575	65	11	cov-2	cov-2	PART
ijpds-3575	65	12	vol	vol	NOUN
ijpds-3575	65	13	1	1	NUM
ijpds-3575	65	14	|	|	ADV
ijpds-3575	65	15	issue	issue	VERB
ijpds-3575	65	16	3	3	NUM
ijpds-3575	65	17	|	|	ADV
ijpds-3575	65	18	oct	oct	PROPN
ijpds-3575	65	19	dec	dec	PROPN
ijpds-3575	65	20	2022	2022	NUM
ijpds-3575	65	21	indian	indian	PROPN
ijpds-3575	65	22	j	j	PROPN
ijpds-3575	65	23	pharm	pharm	PROPN
ijpds-3575	65	24	drug	drug	PROPN
ijpds-3575	65	25	studies	study	NOUN
ijpds-3575	65	26	|	|	ADV
ijpds-3575	65	27	77	77	NUM
ijpds-3575	65	28	nct04477993	nct04477993	NOUN
ijpds-3575	65	29	ruxolitinib	ruxolitinib	PROPN
ijpds-3575	65	30	vanderson	vanderson	PROPN
ijpds-3575	65	31	geraldo	geraldo	PROPN
ijpds-3575	65	32	rocha	rocha	PROPN
ijpds-3575	65	33	terminated	terminate	VERB
ijpds-3575	65	34	5	5	NUM
ijpds-3575	65	35	nct04780581	nct04780581	NOUN
ijpds-3575	65	36	dexamethasone	dexamethasone	NOUN
ijpds-3575	65	37	fundación	fundación	PROPN
ijpds-3575	65	38	instituto	instituto	PROPN
ijpds-3575	65	39	de	de	PROPN
ijpds-3575	65	40	estudios	estudios	PROPN
ijpds-3575	65	41	de	de	PROPN
ijpds-3575	65	42	ciencias	ciencias	PROPN
ijpds-3575	65	43	de	de	PROPN
ijpds-3575	65	44	la	la	PROPN
ijpds-3575	65	45	salud	salud	PROPN
ijpds-3575	65	46	de	de	PROPN
ijpds-3575	65	47	castilla	castilla	PROPN
ijpds-3575	65	48	y	y	PROPN
ijpds-3575	65	49	león	león	PROPN
ijpds-3575	65	50	recruiting	recruit	VERB
ijpds-3575	65	51	290	290	NUM
ijpds-3575	65	52	nct04406246	nct04406246	NOUN
ijpds-3575	65	53	nitazoxanide	nitazoxanide	PROPN
ijpds-3575	65	54	materno	materno	ADJ
ijpds-3575	65	55	-	-	ADJ
ijpds-3575	65	56	perinatal	perinatal	ADJ
ijpds-3575	65	57	hospital	hospital	NOUN
ijpds-3575	65	58	of	of	ADP
ijpds-3575	65	59	the	the	DET
ijpds-3575	65	60	state	state	NOUN
ijpds-3575	65	61	of	of	ADP
ijpds-3575	65	62	mexico	mexico	PROPN
ijpds-3575	65	63	completed	complete	VERB
ijpds-3575	65	64	150	150	NUM
ijpds-3575	65	65	nct04473274	nct04473274	ADJ
ijpds-3575	65	66	pioglitazone	pioglitazone	NOUN
ijpds-3575	65	67	samaritan	samaritan	PROPN
ijpds-3575	65	68	health	health	NOUN
ijpds-3575	65	69	services	service	NOUN
ijpds-3575	65	70	completed	complete	VERB
ijpds-3575	65	71	10	10	NUM
ijpds-3575	65	72	nct04668209	nct04668209	NOUN
ijpds-3575	65	73	cx4549	cx4549	PROPN
ijpds-3575	65	74	university	university	PROPN
ijpds-3575	65	75	of	of	ADP
ijpds-3575	65	76	arizona	arizona	PROPN
ijpds-3575	65	77	recruiting	recruit	VERB
ijpds-3575	65	78	40	40	NUM
ijpds-3575	65	79	nct04414618	nct04414618	NOUN
ijpds-3575	65	80	opaganib	opaganib	NOUN
ijpds-3575	65	81	redhill	redhill	PROPN
ijpds-3575	65	82	biopharma	biopharma	PROPN
ijpds-3575	65	83	limited	limit	VERB
ijpds-3575	65	84	completed	complete	VERB
ijpds-3575	65	85	42	42	NUM
ijpds-3575	65	86	nct04409509	nct04409509	NOUN
ijpds-3575	65	87	csl312	csl312	PROPN
ijpds-3575	65	88	csl	csl	PROPN
ijpds-3575	65	89	behring	behring	NOUN
ijpds-3575	65	90	completed	complete	VERB
ijpds-3575	65	91	124	124	NUM
ijpds-3575	65	92	nct04341116	nct04341116	ADJ
ijpds-3575	65	93	tj003234	tj003234	PROPN
ijpds-3575	65	94	i	i	PROPN
ijpds-3575	65	95	-	-	PUNCT
ijpds-3575	65	96	mab	mab	PROPN
ijpds-3575	65	97	biopharma	biopharma	PROPN
ijpds-3575	65	98	co.	co.	PROPN
ijpds-3575	65	99	ltd	ltd	PROPN
ijpds-3575	65	100	.	.	PROPN
ijpds-3575	65	101	recruiting	recruit	VERB
ijpds-3575	65	102	384	384	NUM
ijpds-3575	65	103	nct04632381	nct04632381	NOUN
ijpds-3575	65	104	zotatifin	zotatifin	NOUN
ijpds-3575	65	105	effector	effector	NOUN
ijpds-3575	65	106	therapeutics	therapeutic	NOUN
ijpds-3575	65	107	recruiting	recruit	VERB
ijpds-3575	65	108	36	36	NUM
ijpds-3575	65	109	nct04672564	nct04672564	ADV
ijpds-3575	65	110	carrimycin	carrimycin	VERB
ijpds-3575	65	111	shenyang	shenyang	PROPN
ijpds-3575	65	112	tonglian	tonglian	PROPN
ijpds-3575	65	113	group	group	PROPN
ijpds-3575	65	114	co.	co.	PROPN
ijpds-3575	65	115	,	,	PUNCT
ijpds-3575	65	116	ltd	ltd	ADJ
ijpds-3575	65	117	recruiting	recruit	VERB
ijpds-3575	65	118	300	300	NUM
ijpds-3575	65	119	mechanism	mechanism	NOUN
ijpds-3575	65	120	of	of	ADP
ijpds-3575	65	121	action	action	NOUN
ijpds-3575	65	122	favipiravir	favipiravir	PROPN
ijpds-3575	65	123	-	-	PUNCT
ijpds-3575	65	124	rtp	rtp	PROPN
ijpds-3575	65	125	binds	bind	VERB
ijpds-3575	65	126	to	to	PART
ijpds-3575	65	127	and	and	CCONJ
ijpds-3575	65	128	inhibits	inhibit	VERB
ijpds-3575	65	129	rdrp	rdrp	PROPN
ijpds-3575	65	130	,	,	PUNCT
ijpds-3575	65	131	which	which	PRON
ijpds-3575	65	132	ultimately	ultimately	ADV
ijpds-3575	65	133	prevents	prevent	VERB
ijpds-3575	65	134	viral	viral	ADJ
ijpds-3575	65	135	transcription	transcription	NOUN
ijpds-3575	65	136	and	and	CCONJ
ijpds-3575	65	137	replication	replication	NOUN
ijpds-3575	65	138	.	.	PUNCT
ijpds-3575	66	1	favipiravir	favipiravir	PROPN
ijpds-3575	66	2	is	be	AUX
ijpds-3575	66	3	a	a	DET
ijpds-3575	66	4	purine	purine	NOUN
ijpds-3575	66	5	base	base	NOUN
ijpds-3575	66	6	analogue	analogue	NOUN
ijpds-3575	66	7	that	that	PRON
ijpds-3575	66	8	is	be	AUX
ijpds-3575	66	9	converted	convert	VERB
ijpds-3575	66	10	to	to	ADP
ijpds-3575	66	11	active	active	ADJ
ijpds-3575	66	12	favipiravir	favipiravir	NOUN
ijpds-3575	66	13	-	-	PUNCT
ijpds-3575	66	14	rtp	rtp	PROPN
ijpds-3575	66	15	by	by	ADP
ijpds-3575	66	16	intracellular	intracellular	ADJ
ijpds-3575	66	17	phosphoribosylation	phosphoribosylation	NOUN
ijpds-3575	66	18	.	.	PUNCT
ijpds-3575	67	1	it	it	PRON
ijpds-3575	67	2	is	be	AUX
ijpds-3575	67	3	a	a	DET
ijpds-3575	67	4	selective	selective	ADJ
ijpds-3575	67	5	and	and	CCONJ
ijpds-3575	67	6	potent	potent	ADJ
ijpds-3575	67	7	inhibitor	inhibitor	NOUN
ijpds-3575	67	8	of	of	ADP
ijpds-3575	67	9	rdrp	rdrp	NOUN
ijpds-3575	67	10	of	of	ADP
ijpds-3575	67	11	rna	rna	NOUN
ijpds-3575	67	12	viruses	virus	NOUN
ijpds-3575	67	13	.	.	PUNCT
ijpds-3575	68	1	favipiravir	favipiravir	PROPN
ijpds-3575	68	2	is	be	AUX
ijpds-3575	68	3	incorporated	incorporate	VERB
ijpds-3575	68	4	into	into	ADP
ijpds-3575	68	5	the	the	DET
ijpds-3575	68	6	nascent	nascent	ADJ
ijpds-3575	68	7	viral	viral	ADJ
ijpds-3575	68	8	rna	rna	NOUN
ijpds-3575	68	9	by	by	ADP
ijpds-3575	68	10	error	error	NOUN
ijpds-3575	68	11	-	-	PUNCT
ijpds-3575	68	12	prone	prone	ADJ
ijpds-3575	68	13	viral	viral	ADJ
ijpds-3575	68	14	rdrp	rdrp	NOUN
ijpds-3575	68	15	,	,	PUNCT
ijpds-3575	68	16	which	which	PRON
ijpds-3575	68	17	leads	lead	VERB
ijpds-3575	68	18	to	to	ADP
ijpds-3575	68	19	chain	chain	NOUN
ijpds-3575	68	20	termination	termination	NOUN
ijpds-3575	68	21	and	and	CCONJ
ijpds-3575	68	22	viral	viral	ADJ
ijpds-3575	68	23	mutagenesis	mutagenesis	NOUN
ijpds-3575	68	24	[	[	X
ijpds-3575	68	25	20	20	NUM
ijpds-3575	68	26	]	]	PUNCT
ijpds-3575	68	27	.	.	PUNCT
ijpds-3575	69	1	the	the	DET
ijpds-3575	69	2	rdrp	rdrp	NOUN
ijpds-3575	69	3	existing	exist	VERB
ijpds-3575	69	4	in	in	ADP
ijpds-3575	69	5	various	various	ADJ
ijpds-3575	69	6	types	type	NOUN
ijpds-3575	69	7	of	of	ADP
ijpds-3575	69	8	rna	rna	NOUN
ijpds-3575	69	9	viruses	virus	NOUN
ijpds-3575	69	10	enables	enable	VERB
ijpds-3575	69	11	a	a	DET
ijpds-3575	69	12	broader	broad	ADJ
ijpds-3575	69	13	spectrum	spectrum	NOUN
ijpds-3575	69	14	of	of	ADP
ijpds-3575	69	15	antiviral	antiviral	ADJ
ijpds-3575	69	16	activities	activity	NOUN
ijpds-3575	69	17	of	of	ADP
ijpds-3575	69	18	favipiravir	favipiravir	PROPN
ijpds-3575	69	19	.	.	PUNCT
ijpds-3575	70	1	after	after	ADP
ijpds-3575	70	2	rna	rna	NOUN
ijpds-3575	70	3	viral	viral	ADJ
ijpds-3575	70	4	incorporation	incorporation	NOUN
ijpds-3575	70	5	,	,	PUNCT
ijpds-3575	70	6	favipiravir	favipiravir	PROPN
ijpds-3575	70	7	-	-	PUNCT
ijpds-3575	70	8	rtp	rtp	PROPN
ijpds-3575	70	9	works	work	VERB
ijpds-3575	70	10	as	as	ADP
ijpds-3575	70	11	a	a	DET
ijpds-3575	70	12	mutagen	mutagen	NOUN
ijpds-3575	70	13	,	,	PUNCT
ijpds-3575	70	14	which	which	PRON
ijpds-3575	70	15	is	be	AUX
ijpds-3575	70	16	capable	capable	ADJ
ijpds-3575	70	17	of	of	ADP
ijpds-3575	70	18	fleeing	flee	VERB
ijpds-3575	70	19	coronavirus	coronavirus	NOUN
ijpds-3575	70	20	repair	repair	NOUN
ijpds-3575	70	21	machinery	machinery	NOUN
ijpds-3575	70	22	.	.	PUNCT
ijpds-3575	71	1	the	the	DET
ijpds-3575	71	2	favipiravir	favipiravir	PROPN
ijpds-3575	71	3	-	-	PUNCT
ijpds-3575	71	4	rtp	rtp	PROPN
ijpds-3575	71	5	adds	add	VERB
ijpds-3575	71	6	to	to	ADP
ijpds-3575	71	7	the	the	DET
ijpds-3575	71	8	pressure	pressure	NOUN
ijpds-3575	71	9	on	on	ADP
ijpds-3575	71	10	cov	cov	PROPN
ijpds-3575	71	11	nucleotide	nucleotide	PROPN
ijpds-3575	71	12	content	content	PROPN
ijpds-3575	71	13	,	,	PUNCT
ijpds-3575	71	14	which	which	PRON
ijpds-3575	71	15	already	already	ADV
ijpds-3575	71	16	has	have	VERB
ijpds-3575	71	17	a	a	DET
ijpds-3575	71	18	low	low	ADJ
ijpds-3575	71	19	cytosine	cytosine	NOUN
ijpds-3575	71	20	in	in	ADP
ijpds-3575	71	21	the	the	DET
ijpds-3575	71	22	sarscov-2	sarscov-2	NUM
ijpds-3575	71	23	genome	genome	NOUN
ijpds-3575	71	24	.	.	PUNCT
ijpds-3575	72	1	in	in	ADP
ijpds-3575	72	2	total	total	NOUN
ijpds-3575	72	3	,	,	PUNCT
ijpds-3575	72	4	along	along	ADP
ijpds-3575	72	5	with	with	ADP
ijpds-3575	72	6	the	the	DET
ijpds-3575	72	7	increased	increase	VERB
ijpds-3575	72	8	frequency	frequency	NOUN
ijpds-3575	72	9	of	of	ADP
ijpds-3575	72	10	mutation	mutation	NOUN
ijpds-3575	72	11	,	,	PUNCT
ijpds-3575	72	12	favipiravir	favipiravir	PROPN
ijpds-3575	72	13	-	-	PUNCT
ijpds-3575	72	14	rtp	rtp	PROPN
ijpds-3575	72	15	has	have	VERB
ijpds-3575	72	16	a	a	DET
ijpds-3575	72	17	positive	positive	ADJ
ijpds-3575	72	18	effect	effect	NOUN
ijpds-3575	72	19	on	on	ADP
ijpds-3575	72	20	sarscov2	sarscov2	NOUN
ijpds-3575	72	21	by	by	ADP
ijpds-3575	72	22	a	a	DET
ijpds-3575	72	23	cytopathic	cytopathic	ADJ
ijpds-3575	72	24	effect	effect	NOUN
ijpds-3575	72	25	,	,	PUNCT
ijpds-3575	72	26	which	which	PRON
ijpds-3575	72	27	is	be	AUX
ijpds-3575	72	28	induced	induce	VERB
ijpds-3575	72	29	by	by	ADP
ijpds-3575	72	30	the	the	DET
ijpds-3575	72	31	virus	virus	NOUN
ijpds-3575	72	32	,	,	PUNCT
ijpds-3575	72	33	reduction	reduction	NOUN
ijpds-3575	72	34	in	in	ADP
ijpds-3575	72	35	the	the	DET
ijpds-3575	72	36	number	number	NOUN
ijpds-3575	72	37	of	of	ADP
ijpds-3575	72	38	viral	viral	ADJ
ijpds-3575	72	39	rna	rna	NOUN
ijpds-3575	72	40	,	,	PUNCT
ijpds-3575	72	41	and	and	CCONJ
ijpds-3575	72	42	infectious	infectious	ADJ
ijpds-3575	72	43	particles	particle	NOUN
ijpds-3575	72	44	.	.	PUNCT
ijpds-3575	73	1	favipiravir	favipiravir	PROPN
ijpds-3575	73	2	has	have	VERB
ijpds-3575	73	3	a	a	DET
ijpds-3575	73	4	strong	strong	ADJ
ijpds-3575	73	5	binding	bind	VERB
ijpds-3575	73	6	affinity	affinity	NOUN
ijpds-3575	73	7	to	to	PART
ijpds-3575	73	8	rdrp	rdrp	VERB
ijpds-3575	73	9	with	with	ADP
ijpds-3575	73	10	a	a	DET
ijpds-3575	73	11	docking	dock	VERB
ijpds-3575	73	12	score	score	NOUN
ijpds-3575	73	13	of	of	ADP
ijpds-3575	73	14	6.925	6.925	NUM
ijpds-3575	73	15	.	.	PUNCT
ijpds-3575	74	1	hence	hence	ADV
ijpds-3575	74	2	,	,	PUNCT
ijpds-3575	74	3	targets	target	VERB
ijpds-3575	74	4	the	the	DET
ijpds-3575	74	5	achilles	achille	NOUN
ijpds-3575	74	6	heel	heel	NOUN
ijpds-3575	74	7	(	(	PUNCT
ijpds-3575	74	8	rdrp	rdrp	NOUN
ijpds-3575	74	9	complex	complex	NOUN
ijpds-3575	74	10	)	)	PUNCT
ijpds-3575	74	11	of	of	ADP
ijpds-3575	74	12	sars	sar	NOUN
ijpds-3575	74	13	-	-	PUNCT
ijpds-3575	74	14	cov-2	cov-2	NOUN
ijpds-3575	74	15	.	.	PUNCT
ijpds-3575	75	1	miscellaneous	miscellaneous	ADJ
ijpds-3575	75	2	anti	anti	ADJ
ijpds-3575	75	3	-	-	ADJ
ijpds-3575	75	4	viral	viral	ADJ
ijpds-3575	75	5	agents	agent	NOUN
ijpds-3575	75	6	in	in	ADP
ijpds-3575	75	7	the	the	DET
ijpds-3575	75	8	therapeutics	therapeutic	NOUN
ijpds-3575	75	9	of	of	ADP
ijpds-3575	75	10	sars	sar	NOUN
ijpds-3575	75	11	-	-	PUNCT
ijpds-3575	75	12	cov-2	cov-2	NOUN
ijpds-3575	75	13	we	we	PRON
ijpds-3575	75	14	have	have	AUX
ijpds-3575	75	15	also	also	ADV
ijpds-3575	75	16	elaborated	elaborate	VERB
ijpds-3575	75	17	the	the	DET
ijpds-3575	75	18	list	list	NOUN
ijpds-3575	75	19	of	of	ADP
ijpds-3575	75	20	other	other	ADJ
ijpds-3575	75	21	drugs	drug	NOUN
ijpds-3575	75	22	that	that	PRON
ijpds-3575	75	23	are	be	AUX
ijpds-3575	75	24	being	be	AUX
ijpds-3575	75	25	employed	employ	VERB
ijpds-3575	75	26	in	in	ADP
ijpds-3575	75	27	the	the	DET
ijpds-3575	75	28	treatment	treatment	NOUN
ijpds-3575	75	29	of	of	ADP
ijpds-3575	75	30	covid-19	covid-19	PROPN
ijpds-3575	75	31	.	.	PUNCT
ijpds-3575	76	1	there	there	PRON
ijpds-3575	76	2	are	be	VERB
ijpds-3575	76	3	several	several	ADJ
ijpds-3575	76	4	kinds	kind	NOUN
ijpds-3575	76	5	of	of	ADP
ijpds-3575	76	6	anti	anti	ADJ
ijpds-3575	76	7	-	-	ADJ
ijpds-3575	76	8	viral	viral	ADJ
ijpds-3575	76	9	drugs	drug	NOUN
ijpds-3575	76	10	other	other	ADJ
ijpds-3575	76	11	than	than	ADP
ijpds-3575	76	12	molnupiravir	molnupiravir	PROPN
ijpds-3575	76	13	and	and	CCONJ
ijpds-3575	76	14	favipiravir	favipiravir	NOUN
ijpds-3575	76	15	for	for	ADP
ijpds-3575	76	16	the	the	DET
ijpds-3575	76	17	treatment	treatment	NOUN
ijpds-3575	76	18	of	of	ADP
ijpds-3575	76	19	covid-19	covid-19	PROPN
ijpds-3575	76	20	.	.	PUNCT
ijpds-3575	77	1	clinical	clinical	ADJ
ijpds-3575	77	2	data	datum	NOUN
ijpds-3575	77	3	major	major	ADJ
ijpds-3575	77	4	drugs	drug	NOUN
ijpds-3575	77	5	that	that	PRON
ijpds-3575	77	6	are	be	AUX
ijpds-3575	77	7	under	under	ADP
ijpds-3575	77	8	clinical	clinical	ADJ
ijpds-3575	77	9	trial	trial	NOUN
ijpds-3575	77	10	of	of	ADP
ijpds-3575	77	11	various	various	ADJ
ijpds-3575	77	12	drugs	drug	NOUN
ijpds-3575	77	13	under	under	ADP
ijpds-3575	77	14	several	several	ADJ
ijpds-3575	77	15	phases	phase	NOUN
ijpds-3575	77	16	for	for	ADP
ijpds-3575	77	17	the	the	DET
ijpds-3575	77	18	development	development	NOUN
ijpds-3575	77	19	of	of	ADP
ijpds-3575	77	20	new	new	ADJ
ijpds-3575	77	21	pharmaceutical	pharmaceutical	NOUN
ijpds-3575	77	22	medicament	medicament	NOUN
ijpds-3575	77	23	for	for	ADP
ijpds-3575	77	24	the	the	DET
ijpds-3575	77	25	treatment	treatment	NOUN
ijpds-3575	77	26	of	of	ADP
ijpds-3575	77	27	sarscov-2	sarscov-2	NUM
ijpds-3575	77	28	from	from	ADP
ijpds-3575	77	29	different	different	ADJ
ijpds-3575	77	30	genera	genera	NOUN
ijpds-3575	77	31	(	(	PUNCT
ijpds-3575	77	32	or	or	CCONJ
ijpds-3575	77	33	different	different	ADJ
ijpds-3575	77	34	classes	class	NOUN
ijpds-3575	77	35	of	of	ADP
ijpds-3575	77	36	drugs	drug	NOUN
ijpds-3575	77	37	)	)	PUNCT
ijpds-3575	77	38	are	be	AUX
ijpds-3575	77	39	entitled	entitle	VERB
ijpds-3575	77	40	in	in	ADP
ijpds-3575	77	41	the	the	DET
ijpds-3575	77	42	table	table	NOUN
ijpds-3575	77	43	3	3	NUM
ijpds-3575	77	44	.	.	X
ijpds-3575	77	45	conclusion	conclusion	NOUN
ijpds-3575	77	46	and	and	CCONJ
ijpds-3575	77	47	future	future	ADJ
ijpds-3575	77	48	scope	scope	NOUN
ijpds-3575	77	49	the	the	DET
ijpds-3575	77	50	review	review	NOUN
ijpds-3575	77	51	concludes	conclude	VERB
ijpds-3575	77	52	that	that	SCONJ
ijpds-3575	77	53	antivirals	antiviral	NOUN
ijpds-3575	77	54	used	use	VERB
ijpds-3575	77	55	in	in	ADP
ijpds-3575	77	56	the	the	DET
ijpds-3575	77	57	treatment	treatment	NOUN
ijpds-3575	77	58	of	of	ADP
ijpds-3575	77	59	coronavirus	coronavirus	NOUN
ijpds-3575	77	60	can	can	AUX
ijpds-3575	77	61	serve	serve	VERB
ijpds-3575	77	62	excellent	excellent	ADJ
ijpds-3575	77	63	in	in	ADP
ijpds-3575	77	64	treatment	treatment	NOUN
ijpds-3575	77	65	.	.	PUNCT
ijpds-3575	78	1	anti	anti	ADJ
ijpds-3575	78	2	-	-	ADJ
ijpds-3575	78	3	viral	viral	ADJ
ijpds-3575	78	4	drugs	drug	NOUN
ijpds-3575	78	5	prevent	prevent	VERB
ijpds-3575	78	6	viral	viral	ADJ
ijpds-3575	78	7	replication	replication	NOUN
ijpds-3575	78	8	through	through	ADP
ijpds-3575	78	9	several	several	ADJ
ijpds-3575	78	10	kinds	kind	NOUN
ijpds-3575	78	11	of	of	ADP
ijpds-3575	78	12	mechanisms	mechanism	NOUN
ijpds-3575	78	13	or	or	CCONJ
ijpds-3575	78	14	physiology	physiology	NOUN
ijpds-3575	78	15	.	.	PUNCT
ijpds-3575	79	1	this	this	DET
ijpds-3575	79	2	review	review	NOUN
ijpds-3575	79	3	justifies	justify	VERB
ijpds-3575	79	4	that	that	SCONJ
ijpds-3575	79	5	molnupiravir	molnupiravir	PROPN
ijpds-3575	79	6	(	(	PUNCT
ijpds-3575	79	7	mk4482	mk4482	PROPN
ijpds-3575	79	8	)	)	PUNCT
ijpds-3575	79	9	is	be	AUX
ijpds-3575	79	10	a	a	DET
ijpds-3575	79	11	prodrug	prodrug	NOUN
ijpds-3575	79	12	used	use	VERB
ijpds-3575	79	13	to	to	PART
ijpds-3575	79	14	treat	treat	VERB
ijpds-3575	79	15	mild	mild	ADJ
ijpds-3575	79	16	-	-	PUNCT
ijpds-3575	79	17	to	to	ADP
ijpds-3575	79	18	-	-	PUNCT
ijpds-3575	79	19	moderate	moderate	ADJ
ijpds-3575	79	20	covid-19	covid-19	PROPN
ijpds-3575	79	21	.	.	PROPN
ijpds-3575	79	22	mk-4482	mk-4482	PROPN
ijpds-3575	79	23	is	be	AUX
ijpds-3575	79	24	the	the	DET
ijpds-3575	79	25	first	first	ADJ
ijpds-3575	79	26	oral	oral	ADJ
ijpds-3575	79	27	,	,	PUNCT
ijpds-3575	79	28	direct	direct	ADJ
ijpds-3575	79	29	-	-	PUNCT
ijpds-3575	79	30	acting	act	VERB
ijpds-3575	79	31	antiviral	antiviral	NOUN
ijpds-3575	79	32	that	that	PRON
ijpds-3575	79	33	shows	show	VERB
ijpds-3575	79	34	highly	highly	ADV
ijpds-3575	79	35	effective	effective	ADJ
ijpds-3575	79	36	at	at	ADP
ijpds-3575	79	37	reducing	reduce	VERB
ijpds-3575	79	38	nasopharyngeal	nasopharyngeal	ADJ
ijpds-3575	79	39	sars	sar	NOUN
ijpds-3575	79	40	-	-	PUNCT
ijpds-3575	79	41	cov-2	cov-2	PART
ijpds-3575	79	42	infection	infection	NOUN
ijpds-3575	79	43	.	.	PUNCT
ijpds-3575	80	1	favipiravir	favipiravir	PROPN
ijpds-3575	80	2	act	act	VERB
ijpds-3575	80	3	as	as	ADP
ijpds-3575	80	4	a	a	DET
ijpds-3575	80	5	prodrug	prodrug	NOUN
ijpds-3575	80	6	and	and	CCONJ
ijpds-3575	80	7	undergoes	undergo	VERB
ijpds-3575	80	8	ribosylations	ribosylation	NOUN
ijpds-3575	80	9	and	and	CCONJ
ijpds-3575	80	10	phosphorylation	phosphorylation	NOUN
ijpds-3575	80	11	intracellularly	intracellularly	ADV
ijpds-3575	80	12	to	to	PART
ijpds-3575	80	13	become	become	VERB
ijpds-3575	80	14	active	active	ADJ
ijpds-3575	80	15	favipiravir	favipiravir	NOUN
ijpds-3575	80	16	-	-	PUNCT
ijpds-3575	80	17	rtp	rtp	PROPN
ijpds-3575	80	18	.	.	PUNCT
ijpds-3575	81	1	this	this	DET
ijpds-3575	81	2	drug	drug	NOUN
ijpds-3575	81	3	inhibits	inhibit	VERB
ijpds-3575	81	4	rdrp	rdrp	NOUN
ijpds-3575	81	5	at	at	ADP
ijpds-3575	81	6	long	long	ADV
ijpds-3575	81	7	last	last	ADJ
ijpds-3575	81	8	prevent	prevent	ADJ
ijpds-3575	81	9	viral	viral	ADJ
ijpds-3575	81	10	transcription	transcription	NOUN
ijpds-3575	81	11	and	and	CCONJ
ijpds-3575	81	12	replication	replication	NOUN
ijpds-3575	81	13	.	.	PUNCT
ijpds-3575	82	1	both	both	DET
ijpds-3575	82	2	drugs	drug	NOUN
ijpds-3575	82	3	are	be	AUX
ijpds-3575	82	4	not	not	PART
ijpds-3575	82	5	preferred	prefer	VERB
ijpds-3575	82	6	in	in	ADP
ijpds-3575	82	7	pregnancy	pregnancy	NOUN
ijpds-3575	82	8	because	because	SCONJ
ijpds-3575	82	9	several	several	ADJ
ijpds-3575	82	10	studies	study	NOUN
ijpds-3575	82	11	and	and	CCONJ
ijpds-3575	82	12	evidence	evidence	NOUN
ijpds-3575	82	13	show	show	VERB
ijpds-3575	82	14	that	that	SCONJ
ijpds-3575	82	15	molnupiravir	molnupiravir	PROPN
ijpds-3575	82	16	causes	cause	VERB
ijpds-3575	82	17	fetal	fetal	ADJ
ijpds-3575	82	18	harm	harm	NOUN
ijpds-3575	82	19	.	.	PUNCT
ijpds-3575	83	1	during	during	ADP
ijpds-3575	83	2	clinical	clinical	ADJ
ijpds-3575	83	3	treatment	treatment	NOUN
ijpds-3575	83	4	,	,	PUNCT
ijpds-3575	83	5	these	these	DET
ijpds-3575	83	6	newer	new	ADJ
ijpds-3575	83	7	generation	generation	NOUN
ijpds-3575	83	8	drugs	drug	NOUN
ijpds-3575	83	9	serve	serve	VERB
ijpds-3575	83	10	as	as	ADP
ijpds-3575	83	11	a	a	DET
ijpds-3575	83	12	potential	potential	ADJ
ijpds-3575	83	13	drug	drug	NOUN
ijpds-3575	83	14	for	for	ADP
ijpds-3575	83	15	the	the	DET
ijpds-3575	83	16	therapeutics	therapeutic	NOUN
ijpds-3575	83	17	of	of	ADP
ijpds-3575	83	18	covid-19	covid-19	PROPN
ijpds-3575	83	19	.	.	PUNCT
ijpds-3575	84	1	intensive	intensive	ADJ
ijpds-3575	84	2	investigations	investigation	NOUN
ijpds-3575	84	3	related	relate	VERB
ijpds-3575	84	4	to	to	ADP
ijpds-3575	84	5	antiviral	antiviral	ADJ
ijpds-3575	84	6	drugs	drug	NOUN
ijpds-3575	84	7	that	that	PRON
ijpds-3575	84	8	are	be	AUX
ijpds-3575	84	9	utilized	utilize	VERB
ijpds-3575	84	10	in	in	ADP
ijpds-3575	84	11	the	the	DET
ijpds-3575	84	12	therapeutics	therapeutic	NOUN
ijpds-3575	84	13	of	of	ADP
ijpds-3575	84	14	sars	sar	NOUN
ijpds-3575	84	15	-	-	PUNCT
ijpds-3575	84	16	cov-2	cov-2	NOUN
ijpds-3575	84	17	for	for	ADP
ijpds-3575	84	18	specific	specific	ADJ
ijpds-3575	84	19	pharmacological	pharmacological	ADJ
ijpds-3575	84	20	actions	action	NOUN
ijpds-3575	84	21	,	,	PUNCT
ijpds-3575	84	22	and	and	CCONJ
ijpds-3575	84	23	their	their	PRON
ijpds-3575	84	24	mechanism	mechanism	NOUN
ijpds-3575	84	25	of	of	ADP
ijpds-3575	84	26	action	action	NOUN
ijpds-3575	84	27	,	,	PUNCT
ijpds-3575	84	28	safety	safety	NOUN
ijpds-3575	84	29	,	,	PUNCT
ijpds-3575	84	30	and	and	CCONJ
ijpds-3575	84	31	efficacy	efficacy	NOUN
ijpds-3575	84	32	could	could	AUX
ijpds-3575	84	33	be	be	AUX
ijpds-3575	84	34	the	the	DET
ijpds-3575	84	35	future	future	ADJ
ijpds-3575	84	36	research	research	NOUN
ijpds-3575	84	37	interest	interest	NOUN
ijpds-3575	84	38	to	to	PART
ijpds-3575	84	39	explore	explore	VERB
ijpds-3575	84	40	the	the	DET
ijpds-3575	84	41	drugs	drug	NOUN
ijpds-3575	84	42	exhaustively	exhaustively	ADV
ijpds-3575	84	43	.	.	PUNCT
ijpds-3575	85	1	there	there	PRON
ijpds-3575	85	2	is	be	VERB
ijpds-3575	85	3	still	still	ADV
ijpds-3575	85	4	an	an	DET
ijpds-3575	85	5	ever	ever	ADV
ijpds-3575	85	6	-	-	PUNCT
ijpds-3575	85	7	increasing	increase	VERB
ijpds-3575	85	8	need	need	NOUN
ijpds-3575	85	9	for	for	ADP
ijpds-3575	85	10	high	high	ADJ
ijpds-3575	85	11	quality	quality	NOUN
ijpds-3575	85	12	evidence	evidence	NOUN
ijpds-3575	85	13	to	to	PART
ijpds-3575	85	14	investigate	investigate	VERB
ijpds-3575	85	15	newer	new	ADJ
ijpds-3575	85	16	and	and	CCONJ
ijpds-3575	85	17	effective	effective	ADJ
ijpds-3575	85	18	therapies	therapy	NOUN
ijpds-3575	85	19	for	for	ADP
ijpds-3575	85	20	covid-19	covid-19	PROPN
ijpds-3575	85	21	.	.	PUNCT
ijpds-3575	85	22	abbrevatons	abbrevaton	NOUN
ijpds-3575	86	1	+	+	CCONJ
ijpds-3575	86	2	sgmrna	sgmrna	ADJ
ijpds-3575	86	3	:	:	PUNCT
ijpds-3575	86	4	positive	positive	ADJ
ijpds-3575	86	5	-	-	PUNCT
ijpds-3575	86	6	strand	strand	NOUN
ijpds-3575	86	7	subgenomic	subgenomic	ADJ
ijpds-3575	86	8	mrna	mrna	PROPN
ijpds-3575	86	9	;	;	PUNCT
ijpds-3575	86	10	atp	atp	PROPN
ijpds-3575	86	11	:	:	PUNCT
ijpds-3575	86	12	adenosine	adenosine	NOUN
ijpds-3575	86	13	triphosphate	triphosphate	NOUN
ijpds-3575	86	14	;	;	PUNCT
ijpds-3575	86	15	ctp	ctp	PROPN
ijpds-3575	86	16	:	:	PUNCT
ijpds-3575	86	17	cytidine	cytidine	NOUN
ijpds-3575	86	18	triphosphate	triphosphate	NOUN
ijpds-3575	86	19	;	;	PUNCT
ijpds-3575	86	20	ec	ec	PROPN
ijpds-3575	86	21	:	:	PUNCT
ijpds-3575	86	22	effective	effective	ADJ
ijpds-3575	86	23	concentrations	concentration	NOUN
ijpds-3575	86	24	;	;	PUNCT
ijpds-3575	86	25	eidd	eidd	X
ijpds-3575	86	26	:	:	PUNCT
ijpds-3575	86	27	emory	emory	PROPN
ijpds-3575	86	28	institute	institute	PROPN
ijpds-3575	86	29	for	for	ADP
ijpds-3575	86	30	drug	drug	NOUN
ijpds-3575	86	31	development	development	NOUN
ijpds-3575	86	32	;	;	PUNCT
ijpds-3575	86	33	favipiravir	favipiravir	PROPN
ijpds-3575	86	34	-	-	PUNCT
ijpds-3575	86	35	rtp	rtp	PROPN
ijpds-3575	86	36	:	:	PUNCT
ijpds-3575	86	37	favipiravir	favipiravir	PROPN
ijpds-3575	86	38	ribofuranosyl5b	ribofuranosyl5b	NOUN
ijpds-3575	86	39	-	-	PUNCT
ijpds-3575	86	40	triphosphate	triphosphate	NOUN
ijpds-3575	86	41	;	;	PUNCT
ijpds-3575	86	42	gtp	gtp	NOUN
ijpds-3575	86	43	:	:	PUNCT
ijpds-3575	86	44	guanosine-5’-triphosphate	guanosine-5’-triphosphate	NOUN
ijpds-3575	86	45	;	;	PUNCT
ijpds-3575	86	46	hiv	hiv	PROPN
ijpds-3575	86	47	:	:	PUNCT
ijpds-3575	86	48	human	human	ADJ
ijpds-3575	86	49	immunodeficiency	immunodeficiency	NOUN
ijpds-3575	86	50	virus	virus	NOUN
ijpds-3575	86	51	;	;	PUNCT
ijpds-3575	86	52	rdrp	rdrp	PROPN
ijpds-3575	86	53	:	:	PUNCT
ijpds-3575	86	54	rna	rna	NOUN
ijpds-3575	86	55	-	-	PUNCT
ijpds-3575	86	56	dependent	dependent	ADJ
ijpds-3575	86	57	rna	rna	NOUN
ijpds-3575	86	58	polymerase	polymerase	NOUN
ijpds-3575	86	59	;	;	PUNCT
ijpds-3575	86	60	sars	sar	NOUN
ijpds-3575	86	61	-	-	PUNCT
ijpds-3575	86	62	cov-2	cov-2	NOUN
ijpds-3575	86	63	:	:	PUNCT
ijpds-3575	86	64	severe	severe	ADJ
ijpds-3575	86	65	acute	acute	ADJ
ijpds-3575	86	66	respiratory	respiratory	ADJ
ijpds-3575	86	67	syndrome	syndrome	NOUN
ijpds-3575	86	68	corona	corona	PROPN
ijpds-3575	86	69	virus	virus	NOUN
ijpds-3575	86	70	2	2	NUM
ijpds-3575	86	71	;	;	PUNCT
ijpds-3575	86	72	utp	utp	NOUN
ijpds-3575	86	73	:	:	PUNCT
ijpds-3575	86	74	uridine	uridine	NOUN
ijpds-3575	86	75	triphosphate	triphosphate	NOUN
ijpds-3575	86	76	;	;	PUNCT
ijpds-3575	86	77	voc	voc	NOUN
ijpds-3575	86	78	:	:	PUNCT
ijpds-3575	86	79	variant	variant	NOUN
ijpds-3575	86	80	of	of	ADP
ijpds-3575	86	81	concern	concern	NOUN
ijpds-3575	86	82	;	;	PUNCT
ijpds-3575	86	83	voi	voi	NUM
ijpds-3575	86	84	:	:	PUNCT
ijpds-3575	86	85	variant	variant	NOUN
ijpds-3575	86	86	of	of	ADP
ijpds-3575	86	87	interest	interest	NOUN
ijpds-3575	86	88	.	.	PUNCT
ijpds-3575	87	1	references	reference	NOUN
ijpds-3575	87	2	1	1	NUM
ijpds-3575	87	3	.	.	PUNCT
ijpds-3575	87	4	singh	singh	PROPN
ijpds-3575	87	5	ak	ak	PROPN
ijpds-3575	87	6	,	,	PUNCT
ijpds-3575	87	7	singh	singh	PROPN
ijpds-3575	87	8	a	a	X
ijpds-3575	87	9	,	,	PUNCT
ijpds-3575	87	10	singh	singh	PROPN
ijpds-3575	87	11	r	r	NOUN
ijpds-3575	87	12	,	,	PUNCT
ijpds-3575	87	13	et	et	PROPN
ijpds-3575	87	14	al	al	PROPN
ijpds-3575	87	15	.	.	PROPN
ijpds-3575	87	16	molnupiravir	molnupiravir	PROPN
ijpds-3575	87	17	in	in	ADP
ijpds-3575	87	18	covid-19	covid-19	PROPN
ijpds-3575	87	19	:	:	PUNCT
ijpds-3575	87	20	a	a	DET
ijpds-3575	87	21	systematic	systematic	ADJ
ijpds-3575	87	22	review	review	NOUN
ijpds-3575	87	23	of	of	ADP
ijpds-3575	87	24	literature	literature	NOUN
ijpds-3575	87	25	.	.	PUNCT
ijpds-3575	88	1	diabetes	diabete	VERB
ijpds-3575	88	2	metab	metab	NOUN
ijpds-3575	88	3	syndr	syndr	NOUN
ijpds-3575	89	1	[	[	X
ijpds-3575	89	2	internet	internet	NOUN
ijpds-3575	89	3	]	]	PUNCT
ijpds-3575	89	4	.	.	PUNCT
ijpds-3575	90	1	2021	2021	NUM
ijpds-3575	90	2	;	;	PUNCT
ijpds-3575	91	1	15(6	15(6	NUM
ijpds-3575	91	2	):	):	PUNCT
ijpds-3575	91	3	102329	102329	NUM
ijpds-3575	91	4	.	.	PUNCT
ijpds-3575	92	1	2	2	X
ijpds-3575	92	2	.	.	X
ijpds-3575	92	3	zarenezhad	zarenezhad	PROPN
ijpds-3575	92	4	e	e	NOUN
ijpds-3575	92	5	,	,	PUNCT
ijpds-3575	92	6	marzi	marzi	ADJ
ijpds-3575	92	7	m.	m.	NOUN
ijpds-3575	92	8	review	review	NOUN
ijpds-3575	92	9	on	on	ADP
ijpds-3575	92	10	molnupiravir	molnupiravir	PROPN
ijpds-3575	92	11	as	as	ADP
ijpds-3575	92	12	a	a	DET
ijpds-3575	92	13	promising	promising	ADJ
ijpds-3575	92	14	oral	oral	ADJ
ijpds-3575	92	15	drug	drug	NOUN
ijpds-3575	92	16	for	for	ADP
ijpds-3575	92	17	the	the	DET
ijpds-3575	92	18	treatment	treatment	NOUN
ijpds-3575	92	19	of	of	ADP
ijpds-3575	92	20	covid-19	covid-19	PROPN
ijpds-3575	92	21	.	.	PUNCT
ijpds-3575	92	22	med	med	PROPN
ijpds-3575	92	23	chem	chem	NOUN
ijpds-3575	92	24	res	re	NOUN
ijpds-3575	92	25	[	[	X
ijpds-3575	92	26	internet	internet	NOUN
ijpds-3575	92	27	]	]	PUNCT
ijpds-3575	92	28	.	.	PUNCT
ijpds-3575	93	1	2022	2022	NUM
ijpds-3575	93	2	;	;	PUNCT
ijpds-3575	93	3	31(2	31(2	NUM
ijpds-3575	93	4	):	):	PUNCT
ijpds-3575	93	5	232	232	NUM
ijpds-3575	93	6	-	-	SYM
ijpds-3575	93	7	43	43	NUM
ijpds-3575	93	8	.	.	PUNCT
ijpds-3575	94	1	3	3	X
ijpds-3575	94	2	.	.	X
ijpds-3575	94	3	kabinger	kabinger	PROPN
ijpds-3575	94	4	f	f	PROPN
ijpds-3575	94	5	,	,	PUNCT
ijpds-3575	94	6	stiller	stiller	NOUN
ijpds-3575	94	7	c	c	PROPN
ijpds-3575	94	8	,	,	PUNCT
ijpds-3575	94	9	schmitzová	schmitzová	PROPN
ijpds-3575	94	10	j	j	PROPN
ijpds-3575	94	11	,	,	PUNCT
ijpds-3575	94	12	et	et	PROPN
ijpds-3575	94	13	al	al	PROPN
ijpds-3575	94	14	.	.	PUNCT
ijpds-3575	94	15	mechanism	mechanism	NOUN
ijpds-3575	94	16	of	of	ADP
ijpds-3575	94	17	molnupiravir	molnupiravir	PROPN
ijpds-3575	94	18	-	-	PUNCT
ijpds-3575	94	19	induced	induce	VERB
ijpds-3575	94	20	sars	sar	NOUN
ijpds-3575	94	21	-	-	PUNCT
ijpds-3575	94	22	cov-2	cov-2	NOUN
ijpds-3575	94	23	mutagenesis	mutagenesis	NOUN
ijpds-3575	94	24	.	.	PUNCT
ijpds-3575	95	1	nat	nat	PROPN
ijpds-3575	95	2	struct	struct	NOUN
ijpds-3575	95	3	mol	mol	ADP
ijpds-3575	95	4	biol	biol	PROPN
ijpds-3575	96	1	[	[	X
ijpds-3575	96	2	internet	internet	NOUN
ijpds-3575	96	3	]	]	X
ijpds-3575	96	4	.	.	PUNCT
ijpds-3575	96	5	2021	2021	NUM
ijpds-3575	96	6	;	;	PUNCT
ijpds-3575	96	7	28(9	28(9	NOUN
ijpds-3575	96	8	):	):	PUNCT
ijpds-3575	96	9	740	740	NUM
ijpds-3575	96	10	-	-	SYM
ijpds-3575	96	11	6	6	NUM
ijpds-3575	96	12	.	.	PUNCT
ijpds-3575	97	1	singh	singh	PROPN
ijpds-3575	97	2	et	et	PROPN
ijpds-3575	97	3	al	al	PROPN
ijpds-3575	97	4	.	.	PROPN
ijpds-3575	97	5	molnupiravir	molnupiravir	PROPN
ijpds-3575	97	6	and	and	CCONJ
ijpds-3575	97	7	favipiravir	favipiravir	PROPN
ijpds-3575	97	8	in	in	ADP
ijpds-3575	97	9	sars	sars	PROPN
ijpds-3575	97	10	-	-	PUNCT
ijpds-3575	97	11	cov-2	cov-2	PART
ijpds-3575	97	12	vol	vol	NOUN
ijpds-3575	97	13	1	1	NUM
ijpds-3575	97	14	|	|	ADV
ijpds-3575	97	15	issue	issue	VERB
ijpds-3575	97	16	3	3	NUM
ijpds-3575	97	17	|	|	ADV
ijpds-3575	97	18	oct	oct	PROPN
ijpds-3575	97	19	dec	dec	PROPN
ijpds-3575	97	20	2022	2022	NUM
ijpds-3575	97	21	indian	indian	PROPN
ijpds-3575	97	22	j	j	PROPN
ijpds-3575	97	23	pharm	pharm	PROPN
ijpds-3575	97	24	drug	drug	PROPN
ijpds-3575	97	25	studies	study	NOUN
ijpds-3575	97	26	|	|	ADV
ijpds-3575	97	27	78	78	NUM
ijpds-3575	97	28	4	4	NUM
ijpds-3575	97	29	.	.	PUNCT
ijpds-3575	97	30	baranovich	baranovich	PROPN
ijpds-3575	97	31	t	t	PROPN
ijpds-3575	97	32	,	,	PUNCT
ijpds-3575	97	33	wong	wong	PROPN
ijpds-3575	97	34	s	s	PROPN
ijpds-3575	97	35	-	-	PUNCT
ijpds-3575	97	36	s	s	PROPN
ijpds-3575	97	37	,	,	PUNCT
ijpds-3575	97	38	armstrong	armstrong	PROPN
ijpds-3575	97	39	j	j	PROPN
ijpds-3575	97	40	,	,	PUNCT
ijpds-3575	97	41	et	et	PROPN
ijpds-3575	97	42	al	al	PROPN
ijpds-3575	97	43	.	.	PROPN
ijpds-3575	98	1	t-705	t-705	PROPN
ijpds-3575	98	2	(	(	PUNCT
ijpds-3575	98	3	favipiravir	favipiravir	PROPN
ijpds-3575	98	4	)	)	PUNCT
ijpds-3575	98	5	induces	induce	VERB
ijpds-3575	98	6	lethal	lethal	ADJ
ijpds-3575	98	7	mutagenesis	mutagenesis	NOUN
ijpds-3575	98	8	in	in	ADP
ijpds-3575	98	9	influenza	influenza	NOUN
ijpds-3575	98	10	a	a	DET
ijpds-3575	98	11	h1n1	h1n1	NOUN
ijpds-3575	98	12	virusesin	virusesin	NOUN
ijpds-3575	98	13	vitro	vitro	X
ijpds-3575	98	14	.	.	PUNCT
ijpds-3575	99	1	j	j	PROPN
ijpds-3575	99	2	virol	virol	NOUN
ijpds-3575	100	1	[	[	X
ijpds-3575	100	2	internet	internet	NOUN
ijpds-3575	100	3	]	]	PUNCT
ijpds-3575	100	4	.	.	PUNCT
ijpds-3575	101	1	2013	2013	NUM
ijpds-3575	101	2	;	;	PUNCT
ijpds-3575	101	3	87(7	87(7	NUM
ijpds-3575	101	4	):	):	PUNCT
ijpds-3575	101	5	3741	3741	NUM
ijpds-3575	101	6	-	-	SYM
ijpds-3575	101	7	51	51	NUM
ijpds-3575	101	8	.	.	NOUN
ijpds-3575	102	1	5	5	NUM
ijpds-3575	102	2	.	.	X
ijpds-3575	102	3	reynard	reynard	PROPN
ijpds-3575	102	4	o	o	PROPN
ijpds-3575	102	5	,	,	PUNCT
ijpds-3575	102	6	nguyen	nguyen	NOUN
ijpds-3575	102	7	x	x	X
ijpds-3575	102	8	-	-	PUNCT
ijpds-3575	102	9	n	n	CCONJ
ijpds-3575	102	10	,	,	PUNCT
ijpds-3575	102	11	alazard	alazard	PROPN
ijpds-3575	102	12	-	-	PUNCT
ijpds-3575	102	13	dany	dany	PROPN
ijpds-3575	102	14	n	n	PROPN
ijpds-3575	102	15	,	,	PUNCT
ijpds-3575	102	16	et	et	PROPN
ijpds-3575	102	17	al	al	PROPN
ijpds-3575	102	18	.	.	PUNCT
ijpds-3575	102	19	identification	identification	NOUN
ijpds-3575	102	20	of	of	ADP
ijpds-3575	102	21	a	a	DET
ijpds-3575	102	22	new	new	ADJ
ijpds-3575	102	23	ribonucleoside	ribonucleoside	NOUN
ijpds-3575	102	24	inhibitor	inhibitor	NOUN
ijpds-3575	102	25	of	of	ADP
ijpds-3575	102	26	ebola	ebola	PROPN
ijpds-3575	102	27	virus	virus	NOUN
ijpds-3575	102	28	replication	replication	NOUN
ijpds-3575	102	29	.	.	PUNCT
ijpds-3575	103	1	viruses	virus	NOUN
ijpds-3575	104	1	[	[	X
ijpds-3575	104	2	internet	internet	NOUN
ijpds-3575	104	3	]	]	PUNCT
ijpds-3575	104	4	.	.	PUNCT
ijpds-3575	105	1	2015	2015	NUM
ijpds-3575	105	2	;	;	PUNCT
ijpds-3575	105	3	7(12	7(12	NUM
ijpds-3575	105	4	):	):	PUNCT
ijpds-3575	105	5	6233	6233	NUM
ijpds-3575	105	6	-	-	SYM
ijpds-3575	105	7	40	40	NUM
ijpds-3575	105	8	.	.	NOUN
ijpds-3575	106	1	6	6	NUM
ijpds-3575	106	2	.	.	X
ijpds-3575	106	3	toots	toot	VERB
ijpds-3575	106	4	m	m	PROPN
ijpds-3575	106	5	,	,	PUNCT
ijpds-3575	106	6	yoon	yoon	PROPN
ijpds-3575	106	7	j	j	PROPN
ijpds-3575	106	8	-	-	PROPN
ijpds-3575	106	9	j	j	PROPN
ijpds-3575	106	10	,	,	PUNCT
ijpds-3575	106	11	hart	hart	PROPN
ijpds-3575	106	12	m	m	PROPN
ijpds-3575	106	13	,	,	PUNCT
ijpds-3575	106	14	et	et	PROPN
ijpds-3575	106	15	al	al	PROPN
ijpds-3575	106	16	.	.	PROPN
ijpds-3575	107	1	quantitative	quantitative	ADJ
ijpds-3575	107	2	efficacy	efficacy	PROPN
ijpds-3575	107	3	paradigms	paradigm	NOUN
ijpds-3575	107	4	of	of	ADP
ijpds-3575	107	5	the	the	DET
ijpds-3575	107	6	influenza	influenza	NOUN
ijpds-3575	107	7	clinical	clinical	ADJ
ijpds-3575	107	8	drug	drug	NOUN
ijpds-3575	107	9	candidate	candidate	NOUN
ijpds-3575	107	10	eidd-2801	eidd-2801	NOUN
ijpds-3575	107	11	in	in	ADP
ijpds-3575	107	12	the	the	DET
ijpds-3575	107	13	ferret	ferret	PROPN
ijpds-3575	107	14	model	model	NOUN
ijpds-3575	107	15	.	.	PUNCT
ijpds-3575	108	1	transl	transl	PROPN
ijpds-3575	108	2	res	re	NOUN
ijpds-3575	109	1	[	[	X
ijpds-3575	109	2	internet	internet	NOUN
ijpds-3575	109	3	]	]	PUNCT
ijpds-3575	109	4	.	.	PUNCT
ijpds-3575	110	1	2020	2020	NUM
ijpds-3575	110	2	;	;	PUNCT
ijpds-3575	110	3	218	218	NUM
ijpds-3575	110	4	:	:	PUNCT
ijpds-3575	110	5	16	16	NUM
ijpds-3575	110	6	-	-	SYM
ijpds-3575	110	7	28	28	NUM
ijpds-3575	110	8	.	.	PUNCT
ijpds-3575	111	1	7	7	X
ijpds-3575	111	2	.	.	X
ijpds-3575	111	3	urakova	urakova	PROPN
ijpds-3575	111	4	n	n	CCONJ
ijpds-3575	111	5	,	,	PUNCT
ijpds-3575	111	6	kuznetsova	kuznetsova	PROPN
ijpds-3575	111	7	v	v	ADP
ijpds-3575	111	8	,	,	PUNCT
ijpds-3575	111	9	crossman	crossman	PROPN
ijpds-3575	111	10	dk	dk	PROPN
ijpds-3575	111	11	,	,	PUNCT
ijpds-3575	111	12	et	et	PROPN
ijpds-3575	111	13	al	al	PROPN
ijpds-3575	111	14	.	.	PUNCT
ijpds-3575	111	15	β	β	X
ijpds-3575	111	16	-	-	PUNCT
ijpds-3575	111	17	d	d	NOUN
ijpds-3575	111	18	-n4hydroxycytidine	-n4hydroxycytidine	PROPN
ijpds-3575	111	19	is	be	AUX
ijpds-3575	111	20	a	a	DET
ijpds-3575	111	21	potent	potent	ADJ
ijpds-3575	111	22	anti	anti	ADJ
ijpds-3575	111	23	-	-	ADJ
ijpds-3575	111	24	alphaviru	alphaviru	ADJ
ijpds-3575	111	25	compound	compound	NOUN
ijpds-3575	111	26	that	that	PRON
ijpds-3575	111	27	induces	induce	VERB
ijpds-3575	111	28	a	a	DET
ijpds-3575	111	29	high	high	ADJ
ijpds-3575	111	30	level	level	NOUN
ijpds-3575	111	31	of	of	ADP
ijpds-3575	111	32	mutations	mutation	NOUN
ijpds-3575	111	33	in	in	ADP
ijpds-3575	111	34	the	the	DET
ijpds-3575	111	35	viral	viral	ADJ
ijpds-3575	111	36	genome	genome	NOUN
ijpds-3575	111	37	.	.	PUNCT
ijpds-3575	112	1	j	j	PROPN
ijpds-3575	112	2	virol	virol	NOUN
ijpds-3575	113	1	[	[	X
ijpds-3575	113	2	internet	internet	NOUN
ijpds-3575	113	3	]	]	PUNCT
ijpds-3575	113	4	.	.	PUNCT
ijpds-3575	114	1	2018	2018	NUM
ijpds-3575	114	2	;	;	PUNCT
ijpds-3575	114	3	92(3	92(3	X
ijpds-3575	114	4	)	)	PUNCT
ijpds-3575	114	5	.	.	PUNCT
ijpds-3575	115	1	8	8	X
ijpds-3575	115	2	.	.	X
ijpds-3575	115	3	painter	painter	NOUN
ijpds-3575	115	4	,	,	PUNCT
ijpds-3575	115	5	george	george	PROPN
ijpds-3575	115	6	r	r	PROPN
ijpds-3575	115	7	,	,	PUNCT
ijpds-3575	115	8	bluemling	bluemling	NOUN
ijpds-3575	115	9	,	,	PUNCT
ijpds-3575	115	10	et	et	PROPN
ijpds-3575	115	11	al	al	PROPN
ijpds-3575	115	12	.	.	PUNCT
ijpds-3575	116	1	n4	n4	PROPN
ijpds-3575	116	2	-	-	PUNCT
ijpds-3575	116	3	hydroxycytidine	hydroxycytidine	PROPN
ijpds-3575	116	4	and	and	CCONJ
ijpds-3575	116	5	derivatives	derivative	NOUN
ijpds-3575	116	6	and	and	CCONJ
ijpds-3575	116	7	anti	anti	ADJ
ijpds-3575	116	8	-	-	ADJ
ijpds-3575	116	9	viral	viral	ADJ
ijpds-3575	116	10	uses	use	NOUN
ijpds-3575	116	11	related	relate	VERB
ijpds-3575	116	12	there	there	ADV
ijpds-3575	116	13	to	to	ADP
ijpds-3575	116	14	published	publish	VERB
ijpds-3575	116	15	2020	2020	NUM
ijpds-3575	116	16	-	-	SYM
ijpds-3575	116	17	0903	0903	NUM
ijpds-3575	116	18	,	,	PUNCT
ijpds-3575	116	19	assigned	assign	VERB
ijpds-3575	116	20	to	to	ADP
ijpds-3575	116	21	emory	emory	PROPN
ijpds-3575	116	22	university	university	PROPN
ijpds-3575	116	23	.	.	PUNCT
ijpds-3575	117	1	9	9	NUM
ijpds-3575	117	2	.	.	X
ijpds-3575	117	3	clinicaltrials.gov	clinicaltrials.gov	X
ijpds-3575	117	4	nct04405739	nct04405739	NOUN
ijpds-3575	117	5	.	.	PUNCT
ijpds-3575	118	1	the	the	DET
ijpds-3575	118	2	safety	safety	NOUN
ijpds-3575	118	3	of	of	ADP
ijpds-3575	118	4	molnupiravir	molnupiravir	PROPN
ijpds-3575	118	5	(	(	PUNCT
ijpds-3575	118	6	eidd-2801	eidd-2801	X
ijpds-3575	118	7	)	)	PUNCT
ijpds-3575	118	8	and	and	CCONJ
ijpds-3575	118	9	its	its	PRON
ijpds-3575	118	10	effect	effect	NOUN
ijpds-3575	118	11	on	on	ADP
ijpds-3575	118	12	viral	viral	ADJ
ijpds-3575	118	13	shedding	shedding	NOUN
ijpds-3575	118	14	of	of	ADP
ijpds-3575	118	15	sars	sar	NOUN
ijpds-3575	118	16	-	-	PUNCT
ijpds-3575	118	17	cov2	cov2	PROPN
ijpds-3575	118	18	(	(	PUNCT
ijpds-3575	118	19	end	end	NOUN
ijpds-3575	118	20	-	-	PUNCT
ijpds-3575	118	21	covid	covid	NOUN
ijpds-3575	118	22	)	)	PUNCT
ijpds-3575	118	23	10	10	NUM
ijpds-3575	118	24	.	.	PUNCT
ijpds-3575	119	1	clinicaltrails.gov	clinicaltrails.gov	X
ijpds-3575	119	2	nct04402203	nct04402203	NOUN
ijpds-3575	119	3	.	.	PUNCT
ijpds-3575	120	1	study	study	NOUN
ijpds-3575	120	2	on	on	ADP
ijpds-3575	120	3	safety	safety	NOUN
ijpds-3575	120	4	and	and	CCONJ
ijpds-3575	120	5	efficay	efficay	NOUN
ijpds-3575	120	6	of	of	ADP
ijpds-3575	120	7	favipiravir	favipiravir	PROPN
ijpds-3575	120	8	(	(	PUNCT
ijpds-3575	120	9	favipira	favipira	PROPN
ijpds-3575	120	10	)	)	PUNCT
ijpds-3575	120	11	for	for	ADP
ijpds-3575	120	12	covid-19	covid-19	PROPN
ijpds-3575	120	13	patient	patient	NOUN
ijpds-3575	120	14	in	in	ADP
ijpds-3575	120	15	selected	select	VERB
ijpds-3575	120	16	hospitals	hospital	NOUN
ijpds-3575	120	17	of	of	ADP
ijpds-3575	120	18	bangladesh	bangladesh	NOUN
ijpds-3575	120	19	.	.	PUNCT
ijpds-3575	121	1	11	11	NUM
ijpds-3575	121	2	.	.	PUNCT
ijpds-3575	122	1	new	new	ADJ
ijpds-3575	122	2	evidence	evidence	NOUN
ijpds-3575	122	3	on	on	ADP
ijpds-3575	122	4	vui-2020/2021	vui-2020/2021	NOUN
ijpds-3575	122	5	and	and	CCONJ
ijpds-3575	122	6	review	review	NOUN
ijpds-3575	122	7	of	of	ADP
ijpds-3575	122	8	the	the	DET
ijpds-3575	122	9	public	public	ADJ
ijpds-3575	122	10	health	health	NOUN
ijpds-3575	122	11	risk	risk	NOUN
ijpds-3575	122	12	assessment	assessment	NOUN
ijpds-3575	122	13	.	.	PUNCT
ijpds-3575	123	1	15	15	NUM
ijpds-3575	123	2	december	december	PROPN
ijpds-3575	123	3	2020	2020	NUM
ijpds-3575	123	4	.	.	PUNCT
ijpds-3575	124	1	12	12	NUM
ijpds-3575	124	2	.	.	PUNCT
ijpds-3575	125	1	lowe	lowe	PROPN
ijpds-3575	125	2	d	d	PROPN
ijpds-3575	125	3	,	,	PUNCT
ijpds-3575	125	4	“	"	PUNCT
ijpds-3575	125	5	the	the	DET
ijpds-3575	125	6	new	new	ADJ
ijpds-3575	125	7	mutations	mutation	NOUN
ijpds-3575	125	8	”	"	PUNCT
ijpds-3575	125	9	american	american	PROPN
ijpds-3575	125	10	association	association	NOUN
ijpds-3575	125	11	for	for	ADP
ijpds-3575	125	12	the	the	DET
ijpds-3575	125	13	advancement	advancement	NOUN
ijpds-3575	125	14	of	of	ADP
ijpds-3575	125	15	science	science	NOUN
ijpds-3575	125	16	22	22	NUM
ijpds-3575	125	17	december	december	PROPN
ijpds-3575	125	18	2020	2020	NUM
ijpds-3575	125	19	.	.	PUNCT
ijpds-3575	126	1	13	13	NUM
ijpds-3575	126	2	.	.	PUNCT
ijpds-3575	127	1	faria	faria	PROPN
ijpds-3575	127	2	nr	nr	PROPN
ijpds-3575	127	3	,	,	PUNCT
ijpds-3575	127	4	claro	claro	VERB
ijpds-3575	127	5	i	i	PRON
ijpds-3575	127	6	m	m	PROPN
ijpds-3575	127	7	,	,	PUNCT
ijpds-3575	127	8	candido	candido	PROPN
ijpds-3575	127	9	d	d	PROPN
ijpds-3575	127	10	,	,	PUNCT
ijpds-3575	127	11	et	et	PROPN
ijpds-3575	127	12	al	al	PROPN
ijpds-3575	127	13	,	,	PUNCT
ijpds-3575	127	14	“	"	PUNCT
ijpds-3575	127	15	genomic	genomic	ADJ
ijpds-3575	127	16	characterisation	characterisation	NOUN
ijpds-3575	127	17	of	of	ADP
ijpds-3575	127	18	an	an	DET
ijpds-3575	127	19	emergent	emergent	ADJ
ijpds-3575	127	20	sars	sar	NOUN
ijpds-3575	127	21	-	-	PUNCT
ijpds-3575	127	22	cov-2	cov-2	NOUN
ijpds-3575	127	23	lineage	lineage	NOUN
ijpds-3575	127	24	in	in	ADP
ijpds-3575	127	25	manaus	manaus	NOUN
ijpds-3575	127	26	:	:	PUNCT
ijpds-3575	127	27	prelimary	prelimary	ADJ
ijpds-3575	127	28	findings.march	findings.march	NOUN
ijpds-3575	127	29	2021	2021	NUM
ijpds-3575	127	30	.	.	PUNCT
ijpds-3575	128	1	14	14	NUM
ijpds-3575	128	2	.	.	X
ijpds-3575	129	1	cutler	cutler	PROPN
ijpds-3575	129	2	s.	s.	PROPN
ijpds-3575	129	3	“	"	PUNCT
ijpds-3575	129	4	nepal	nepal	ADJ
ijpds-3575	129	5	variant	variant	NOUN
ijpds-3575	129	6	”	"	PUNCT
ijpds-3575	129	7	:	:	PUNCT
ijpds-3575	129	8	what	what	PRON
ijpds-3575	129	9	we	we	PRON
ijpds-3575	129	10	’ve	’ve	AUX
ijpds-3575	129	11	learned	learn	VERB
ijpds-3575	129	12	so	so	ADV
ijpds-3575	129	13	far	far	ADV
ijpds-3575	129	14	.	.	PUNCT
ijpds-3575	130	1	the	the	DET
ijpds-3575	130	2	conversation	conversation	NOUN
ijpds-3575	130	3	[	[	X
ijpds-3575	130	4	internet	internet	NOUN
ijpds-3575	130	5	]	]	PUNCT
ijpds-3575	130	6	.	.	PUNCT
ijpds-3575	131	1	2021	2021	NUM
ijpds-3575	131	2	jun	jun	PROPN
ijpds-3575	131	3	16	16	NUM
ijpds-3575	132	1	[	[	X
ijpds-3575	132	2	cited	cite	VERB
ijpds-3575	132	3	2022	2022	NUM
ijpds-3575	132	4	15	15	NUM
ijpds-3575	132	5	.	.	PUNCT
ijpds-3575	133	1	aug	aug	PROPN
ijpds-3575	133	2	1	1	NUM
ijpds-3575	133	3	]	]	PUNCT
ijpds-3575	133	4	;	;	PUNCT
ijpds-3575	133	5	15	15	NUM
ijpds-3575	133	6	.	.	PUNCT
ijpds-3575	133	7	torjesen	torjesen	PROPN
ijpds-3575	133	8	,	,	PUNCT
ijpds-3575	133	9	ingrid	ingrid	NOUN
ijpds-3575	133	10	,	,	PUNCT
ijpds-3575	133	11	2021	2021	NUM
ijpds-3575	133	12	.	.	PUNCT
ijpds-3575	134	1	covid-19	covid-19	PROPN
ijpds-3575	134	2	;	;	PUNCT
ijpds-3575	134	3	omicron	omicron	PROPN
ijpds-3575	134	4	may	may	AUX
ijpds-3575	134	5	be	be	AUX
ijpds-3575	134	6	more	more	ADV
ijpds-3575	134	7	transmissible	transmissible	ADJ
ijpds-3575	134	8	than	than	ADP
ijpds-3575	134	9	other	other	ADJ
ijpds-3575	134	10	variants	variant	NOUN
ijpds-3575	134	11	.	.	PUNCT
ijpds-3575	135	1	16	16	NUM
ijpds-3575	135	2	.	.	PUNCT
ijpds-3575	136	1	callaway	callaway	PROPN
ijpds-3575	136	2	,	,	PUNCT
ijpds-3575	136	3	ewen	ewen	PROPN
ijpds-3575	136	4	.	.	PUNCT
ijpds-3575	137	1	heavily	heavily	ADV
ijpds-3575	137	2	mutated	mutate	VERB
ijpds-3575	137	3	corona	corona	PROPN
ijpds-3575	137	4	virus	virus	NOUN
ijpds-3575	137	5	2021	2021	NUM
ijpds-3575	137	6	.	.	PUNCT
ijpds-3575	138	1	17	17	NUM
ijpds-3575	138	2	.	.	PUNCT
ijpds-3575	139	1	covid-19	covid-19	PROPN
ijpds-3575	139	2	coronavirus	coronavirus	NOUN
ijpds-3575	139	3	:	:	PUNCT
ijpds-3575	139	4	ultra	ultra	ADJ
ijpds-3575	139	5	-	-	ADJ
ijpds-3575	139	6	contagious	contagious	ADJ
ijpds-3575	139	7	lambda	lambda	ADJ
ijpds-3575	139	8	variant	variant	NOUN
ijpds-3575	139	9	.	.	PUNCT
ijpds-3575	140	1	2021	2021	NUM
ijpds-3575	140	2	;	;	PUNCT
ijpds-3575	140	3	6(7	6(7	NUM
ijpds-3575	140	4	)	)	PUNCT
ijpds-3575	140	5	.	.	PUNCT
ijpds-3575	141	1	18	18	NUM
ijpds-3575	141	2	.	.	PUNCT
ijpds-3575	141	3	o’neill	o’neill	PROPN
ijpds-3575	141	4	l.	l.	PROPN
ijpds-3575	141	5	mu	mu	PROPN
ijpds-3575	141	6	:	:	PUNCT
ijpds-3575	141	7	everything	everything	PRON
ijpds-3575	141	8	you	you	PRON
ijpds-3575	141	9	need	need	VERB
ijpds-3575	141	10	to	to	PART
ijpds-3575	141	11	know	know	VERB
ijpds-3575	141	12	about	about	ADP
ijpds-3575	141	13	the	the	DET
ijpds-3575	141	14	new	new	ADJ
ijpds-3575	141	15	coronavirus	coronavirus	NOUN
ijpds-3575	141	16	variant	variant	NOUN
ijpds-3575	141	17	of	of	ADP
ijpds-3575	141	18	interest	interest	NOUN
ijpds-3575	141	19	.	.	PUNCT
ijpds-3575	142	1	the	the	DET
ijpds-3575	142	2	conversation	conversation	NOUN
ijpds-3575	142	3	[	[	X
ijpds-3575	142	4	internet	internet	NOUN
ijpds-3575	142	5	]	]	PUNCT
ijpds-3575	142	6	.	.	PUNCT
ijpds-3575	143	1	how	how	SCONJ
ijpds-3575	143	2	to	to	PART
ijpds-3575	143	3	cite	cite	VERB
ijpds-3575	143	4	this	this	DET
ijpds-3575	143	5	article	article	NOUN
ijpds-3575	143	6	:	:	PUNCT
ijpds-3575	143	7	ayush	ayush	PROPN
ijpds-3575	143	8	singh	singh	PROPN
ijpds-3575	143	9	,	,	PUNCT
ijpds-3575	143	10	riya	riya	PROPN
ijpds-3575	143	11	sehgal	sehgal	PROPN
ijpds-3575	143	12	,	,	PUNCT
ijpds-3575	143	13	karamjit	karamjit	ADJ
ijpds-3575	143	14	kaur	kaur	PROPN
ijpds-3575	143	15	,	,	PUNCT
ijpds-3575	143	16	manju	manju	PROPN
ijpds-3575	143	17	,	,	PUNCT
ijpds-3575	143	18	jatin	jatin	PROPN
ijpds-3575	143	19	isher	isher	PROPN
ijpds-3575	143	20	,	,	PUNCT
ijpds-3575	143	21	neeru	neeru	PROPN
ijpds-3575	143	22	kumari	kumari	PROPN
ijpds-3575	143	23	.	.	PUNCT
ijpds-3575	144	1	molnupiravir	molnupiravir	PROPN
ijpds-3575	144	2	and	and	CCONJ
ijpds-3575	144	3	favipiravir	favipiravir	NOUN
ijpds-3575	144	4	in	in	ADP
ijpds-3575	144	5	the	the	DET
ijpds-3575	144	6	therapeutics	therapeutic	NOUN
ijpds-3575	144	7	of	of	ADP
ijpds-3575	144	8	sarscov-2	sarscov-2	NUM
ijpds-3575	144	9	a	a	DET
ijpds-3575	144	10	review	review	NOUN
ijpds-3575	144	11	.	.	PUNCT
ijpds-3575	145	1	indian	indian	PROPN
ijpds-3575	145	2	j	j	PROPN
ijpds-3575	145	3	pharm	pharm	PROPN
ijpds-3575	145	4	dug	dig	VERB
ijpds-3575	145	5	studies	study	NOUN
ijpds-3575	145	6	.	.	PUNCT
ijpds-3575	146	1	2022	2022	NUM
ijpds-3575	146	2	:	:	PUNCT
ijpds-3575	146	3	1(3	1(3	NUM
ijpds-3575	146	4	)	)	PUNCT
ijpds-3575	146	5	73	73	NUM
ijpds-3575	146	6	-	-	SYM
ijpds-3575	146	7	78	78	NUM
ijpds-3575	146	8	.	.	PUNCT
ijpds-3575	147	1	funding	funding	NOUN
ijpds-3575	147	2	:	:	PUNCT
ijpds-3575	147	3	none	none	NOUN
ijpds-3575	147	4	conflict	conflict	NOUN
ijpds-3575	147	5	of	of	ADP
ijpds-3575	147	6	interest	interest	NOUN
ijpds-3575	147	7	:	:	PUNCT
ijpds-3575	147	8	none	none	NOUN
ijpds-3575	147	9	stated	state	VERB